{
  "doc_id": "Θεραπευτικά_Πρωτόκολλα_ΕΟΠΕ-10η_Έκδοση",
  "created_date": "2024",
  "country:": "EL",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
      "text": "3SY. KNATHRIUS H.S.H.O.C.H.C.H.C.H.C.H.C.H.C.H.C.H.C.H.C.H.C.H.C.H.C.H.C.H.C.H.C.H.C.H.C.H.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.",
      "start_page": 3,
      "end_page": 9
    },
    {
      "heading": "Covid19, a new special chapter dealing with Vaccines in oncology patients has been added,",
      "text": "of the implementation, its modernization .CA . . . . . . . . . . . . . . . . . . . . . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 10,
      "end_page": 12
    },
    {
      "heading": "1. AC or EC",
      "text": "Doxorubicin 60 mg/m or Epirubici n 75-90 mg/m2, IV Cyclophosphamide 600 mg/m 2, IV",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2. TC",
      "text": "Docetaxel 75 mg/m2, IV Cyclophosphamide 600 mg/m2, I V",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "3. AC or EC + Taxane",
      "text": "Doxorubicin 60 mg/m or Epirubici n 75-90 mg/m2, I Cyclophosphamide 600 mg/m2, IV Paclitaxel 80 mg/m2 IV, each week for 12 cycles DSeomceetioxsel 7 15:- 1a00 mepeg/lmeg2e tIVA, 14444344444444444444444444444444444222222223443333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "4. FEC",
      "text": "5-FU 500 mg/m2, IV Epirubicin 75-100 mg/m2, IV Cyclophosphamide 500 mg/m2 , IV Csametheus i2ω1s: estuary in ngdia α6s kmyoksl FoEuCs for 6 cycles suggests",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "5. FEC + Taxane",
      "text": "5-FU 500 mg/m2, IV Epirubicin 75-100 mg/m2, IV Cyclophosphamide 500 mg/m2 , IV lus, or 175 m g/m m2 IV, Mr Paclitaxel 175 mg/m2 IV, every 21 days for 4 cycles or Dmoeciotaxe:l t7o5 σ-1x0h0h",
      "start_page": 13,
      "end_page": 14
    },
    {
      "heading": "6. TAC",
      "text": "Docetaxel 75 mg/m2, IV Doxorubicin 50 mg/m2, IV Cyclophosphamide 500 mg/m2, IV Csamethe i2h1h: er see gdioach 6ik garden chcolrocrisy muse parnotarthococcyencephalic cherno-cygae in the xygae.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Cyclophosphamide 100mg/m2, days 1 -14, PO",
      "text": "Methotrexate 40 mg/m2 , days 1.8, IV 5-FU 600 mg/m2, days 1.8, IV",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "8. CMF (intravenous)",
      "text": "Cyclophosphamide 600mg/m2, d1+8 Methotrexate 40 mg/m2 , d1+8 5-FU 600 mg/m2, d1+8",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "9. TCH (patients with HER2+ volume)",
      "text": "Docetaxel 75 mg/m2, IV Carboplatin AUC 6, IV Trastuzumab cycles 6 mg/kg, IV (after the charging dose of 8 mg/kg) Every 21 days for 6 cycles, continuation of trastuzumab as the plus 10. TCHP (comple with HER2+ volume) Docetaxel 75 mg/m2, IV Carboplatin AUC 6, IV",
      "start_page": 14,
      "end_page": 15
    },
    {
      "heading": "12. Paclitaxel + Trastuzumab",
      "text": "Paclitaxel 80 mg/m2 IV, each week for 12 cycles Trastuzumab 2 mg/kg, IV (after the charging dose of 4 mg/kg) each week for 12 cycles Asymoleic disease: prraosttueznuommeab 6 e μigl/okg, IgVia and epox 2",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "13. Neratinib",
      "text": "Sneermaetionisb 2:4 0 mg, PO, every day for 12 months for patients with HER2+ tumor who have completed one year of treatment with trastuz it is known whether it benefits patients treated with trastuzumab and pertuzumab. zumab.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "14. Pembrolizumab and Chemotherapy",
      "text": "Pembroizumab: 200 mg every 3 weeks or 400 mg every 6 weeks. During the neoadjuvant phase pembroizumab should be given in combination with chemotherapy for 24 weeks (8 doses of 200 mg every 3 weeks or 4 doses of 400 mg every 6 weeks). During the adjuvant phase of pembroizumab should be administered as α for 27 weeks (9 doses of 200 mg every 3 weeks or 5 doses of 400 mg every 6 weeks)",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "15. Olaparib",
      "text": "Olaparib 300mg twice daily, treatment duration 1 year for patients at increased risk of relapse, HER2 negative and BRCA mutations. For seropositive disease Olaparib may be co-administered with endocrine Alternatives to intravenous administration of trastuzumab may be used the subcutaneous form at a fixed dose of 600 mg (without charging dose) every 3 weeks. Alternatively to intravenous administration of the combination trastuzumab",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "A1. EPOCURATE ORMONOTHERAPY",
      "text": "The standard treatment is administration of tamoxifen (tamoxifen) 20 mg/day acceptable risk factor (associately dosed at a dose of 510 mg/day with a dosed dose of at least 14 mg/day. At least 14 mg/day, the dosed dosed at a dose of 14 mg/day should be considered based on the estimated risk of relapse. ovarian suppression with LHRH analogue. Supplemental administration of LHRH is recommended in patients with hormone-sensitive disease patients.\n\nAlso in all cases of Her2-positive or triple-negative tumors with maximum diameter For patients with luminal A-like tumor A-like tumor is recommended for the lower cases of luminal tumors. For patients with luminal tumors, a combination of chemotherapy with double anti- HER2 is recommended.",
      "start_page": 16,
      "end_page": 19
    },
    {
      "heading": "B. STATISTICAL DISEASE",
      "text": "overexpression/strengthening or not of HER2 (c-erbB-2) the previous treatment (if anthracycline and/or taxane have been administered as adjuvant and interval Generally in patients who have high hormone receptor expression and negative HER2 and if they have not",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "B1. HARMONIOUS DISEASE",
      "text": "Inhibition of cyclodependent quinases 4/6 [CDK4/6 synapse ligandase (abemaciclib, ribociclib) at baseline dosed with ciclozole (letrozole) at anastrozole (anastrozole) at an initial dose of 4/6 [CDK4/6 ligandase (abemoclib, riboclib) at an Inhibase: 2.5 mg/day, anastrozole (astrozole)",
      "start_page": 19,
      "end_page": 20
    },
    {
      "heading": "Tamoxifen. (tamoxifen) 20 mg/day",
      "text": "Cyclodependent kinase inhibitors 4/6 [CDK4/6 (abemaciclib, palbociclib, ribociclib)] will Everolimus has been approved in combination with exemestane for the treatment of advanced breast cancer in postmenopausal HR+/ HER2-women following disease progression in non- 3. Fulvestrant 5.",
      "start_page": 20,
      "end_page": 21
    },
    {
      "heading": "Epirubicin 75-100 mg/m2, IV or doxorubicin 60-75mg/m2, IV Every 21 days",
      "text": "5. or Doxorubicin 20mg/m2, IV weekly.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "8. Vinorelbine 25-30 mg/m2, IV or 60-80 mg/m2, PO, days 1, 8 , every 21 days",
      "text": "Pegylated liposomal doxorubicin (Caelyx) 50 mg/m2, IV Liposomal doxorubicin (Myocet) 60-75 mg/m2, IV Nanoparticle-bound paclitaxel (Abraxane) 260 mg/m2, IV in 30’ infusion",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "12. Gemcitabine 800-1200mg/m2, IV D1, D8 every 21 days",
      "text": "Trastuzumab deruxtecan for HER2 IHC 1+ or 2+/ISH negative after pr",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "mg/kg IV day 1 every 21 days",
      "text": "IVplatuzumab govitecan for hormone-sensitive, HER-2 negative endocrine day-to-day dosed with CDK4/6 and at least 10mg/kg D1, D8 every 21 days 2. Bevacizumab 10 mg/Kg every 14 days, IV+ Paclitaxel 90 mg/m2week Bevacizumab 15 mg/Kg every 21 days\n\nIt is a treatment of choice for patients with de novo metastatic disease and relapsed dose of >12 weeks of administration of Tadumab + subcutaneous dose of Tadumab + intravenous dose of Tadumab + intravenous dose of Tadumab + intravenous dose of Tadumab + Tadumab + Tadumab + Tadumab + Tadumab + Tadumab + Tadumab + Tadumab + Tadumab).\n\nThe regimen of Picatinib plus trastuzumab, and capecitabine-treated patients should be used in the 2nd line of Carboplatin 5AUV, IV, every 21 days, for cases where anthracyclines and/or taxanes have chemotherapy regimens and combinations with bevacizumab reported for Nab-paclitaxel and atezizumab >",
      "start_page": 22,
      "end_page": 31
    },
    {
      "heading": "cancer. J Clin Oncol 2001; 19:3103.",
      "text": "76 surgery plus chemotherapy in HER2-positive Breast-Bramming Cancer Cancer: a randomized, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2021 Jan;22(1):85-97. 72.Tomasz Byrski, Jacek Gronwald.\n\nTumour-agnostic efficiency and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23-12(10): a phase 1/2, open-label, basket trial. Lancet Oncol.",
      "start_page": 32,
      "end_page": 36
    },
    {
      "heading": "C56",
      "text": "a) Stages IA and IB in low modulation volumes (grade 3) b) Stages IC-IV CONSERVATION TREATMENT (MAINTENANCE)",
      "start_page": 37,
      "end_page": 38
    },
    {
      "heading": "I.",
      "text": "Paclitaxel 175 mg/m , IV + Carboplatin AUC-5-7, IV every 3 weeks for 6-8 cycles",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "II.",
      "text": "Paclitaxel 80 mg/m , IV every week + Carboplatin AUC 6 IV every 3 weeks for 6-8 cycles",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "III.",
      "text": "Carboplatin AUC-5-6, IV every 3 weeks for 6-8 cycles",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "IV.",
      "text": "Bevacizumab has been approved in combination with paclitaxel and carboplatin for 6 cycles of treatment, followed by maintenance therapy with Bevacizumab, for first-line treatment of patients with advanced (stage IIIB, IIIC and IV v FIGO) epithelial ovarian cancer,",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "a.",
      "text": "The recommended dose of Bevacizumab is 15 mg/kg body weight given once",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "b.",
      "text": "Treatment with Bevacizumab should be administered with caution during and at risk of bleeding. If bevacizumab is co-administered with chemotherapy to",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "V.",
      "text": "In patients with advanced (stage III and IV v. FIGO) high degree of malignancy epithelial maintenance therapy cancer with PARP inhibitors Niraparib (Zejula) and Olaparib (Lynparza). This indication of Lynparza concerns only patients who have been identified as carriers of pathogenic mutations or potentially pathogenic mutations of genital (germline) and/or somatic (somatic) cells",
      "start_page": 38,
      "end_page": 39
    },
    {
      "heading": "a.",
      "text": "The recommended starting dose of Niraparib is 200 mg (two capsules or two 100 mg film-coated tablets), taken once daily. However, for patients with a body weight of  77 kg and an initial platelet count of  150,000/μMA, the recommended starting dose is 300 mg (three capsules or three 100 mg film-coated tablets), once daily. The decision for Niraparib was based on the random data.",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "VI.",
      "text": "Maintenance therapy with co-administration of Olaparib and Bevacizumab was approved, based on the results of the study PAOLA-1, in patients who have a complete or partial response to Bevacizumab and whose cancer is associated with homologous recombination (HRD) deficiency, defined by the existence of a pathogenic or potentially pathogenic mutation in the genes BRCA1/2 and/or the dose of Olaparib is 300 mg once daily.",
      "start_page": 39,
      "end_page": 40
    },
    {
      "heading": "I.",
      "text": "Platinum-based chemotherapy (Carboplatin or Cisplatin combined again with Paclitaxel or with other a. Pegylated Liposomal Doxorubicin (PLD). b. Gemcitabine. c. Topotecan.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "II.",
      "text": "The combination of Pegylated Liposomal Doxorubicin (PLD) with Trabectedin (Yondelis) (study ET743-OVA-301), indicated in platinum-sensitive recurrence (PFI > 6 months). Trabectedin is given every 3",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "III.",
      "text": "weeks as 3 hour IV injection 1.1 mg/m2, immediately after PLD 30 mg/m2. The combination of Bevacizumab with Carboplatin/Gemcitabine (OCEANS study) or Carboplatin/Paclitaxel (GOG-0213) and continuation of Bevacizumab as a post-chemotherapy treatment. The recommended dose of Bevacizumab is body",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "a.",
      "text": "The recommended daily dose of olaparib in the form of the tablet is 300mg (2 tablets of 150mg of the treatment regimen) dosed at a dose equivalent to a total daily dose of 600mg (RABID) dosed at a dose of at least 300 mg. The dose-adjusted daily dose of olaparib in patients treated with a dose-free regimen of 300 mg.",
      "start_page": 41,
      "end_page": 42
    },
    {
      "heading": "I.",
      "text": "Chemotherapy is recommended with any of the above drugs other than Cisplatin, Carboplatin. Topotecan, PLD or Epirubicin is considered as a novice.",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "II.",
      "text": "The combination of Trabectedin with PLD is not indicated in platinum-resistant recurrence.",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "III.",
      "text": "The combination of Bevacizumab with the above drugs (Gemcitabine, Topotecan, PLD) improves phase III AURELIA. denosumab/month, as long as there are no contraindications to their administration. Note 2: Olaparib as a treatment in patients with advanced ovarian cancer, who have received at least three treatment lines and carry genomic BRCA mutations, have received FDA approval, but have not received a single-stage BRCA mutation.",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "I.",
      "text": "Cisplatin Doxorubicin Epirubicin Cyclophosphamide",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "II.",
      "text": "Docetaxel should be substituted for Paclitaxel if you are allergic to Paclitaxel or if",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "III.",
      "text": "1. 5-FU/leucovorin/oxaliplatin  bevacizumab IV. Capecitabine/oxaliplatin  bevacizumab V. sequential chemotherapy regimens. In these cases i) Irinotecan, ii) Oxaliplatin iii) Vinorelbine after detailed justification by the treating physician iv)Etoposide and v) Tamoxen patients mainly",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "VI.",
      "text": "Microsatellite instability control (MSI) or the immunoresponsive tissue-responsive tissue-responsive tissue-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-resonsive-res.\n\nGrade III total, stage patients greater than IB ii; patients treated with stage IA radiation or greater, regardless of grade iii. Any histological formula other than endometrial iv. Presence of lymphangiform infiltrates According to PORTEC 3 study applied purely to high-risk patients, postoperative administration of radiotherapy (48.6Gy administered at a daily dose of 1.8Gy)\n\nIV blockade of metastatic disease in staging iv. Absence of any other treatment-rapidibular chemotherapy treatment of patients with chemotherapy-rapidumab + IV-interstitial therapy, IV-interstitial therapy, IV-interstitial therapy, IV-interstitial therapy, IV-interstitial therapy, IV-interstitial therapy, IV-interstitial therapy, IV-interstitial therapy, and IV-interstitial therapy, and IV-interstitial therapy.\n\n10. Paclitaxel 175mg/m2, IV + Carboplatin AUC-6, IV, +Durvalumab 1120mg every 3 weeks, for 6 cycles, then continuation with Durvalumab 1500mg , every 4 weeks, in combination with Olaparib 300mg two Carboplatin/paclitaxel.\n\nNote 9: In the study NRG-GHR018/KEYNOTE-868 was seen in the first-line treatment, in patients with stage III-IV, with the exception of patients with carcinoma statistically significant benefit in disease-free survival (PFS) for the combination of Pembroizumab and Chemotherapy (Paclitaxel + carboplatin IV Q3W  6 cycles)",
      "start_page": 43,
      "end_page": 56
    },
    {
      "heading": "Megestrolacetate",
      "text": "Treatment of choice: (Megace®, 160 – 320 mg daily occurrence; oscillational inflammatory inflammability; oscillational inflammatory inflammatory inflammatory inflammatory inflammatory, oscillating inflammatory inflammatory (for endometrioid histologic type only): The other combinations have not been as effective as Meg in resistance to megace denosumab/month, if there are no contraindications for administration.\n\nThe overall response rate (ORR) was found in 45.4% of patients treated with a mean-to-range resolution (DCR) with a mean-to-range response rate of 27.6 months compared to a mean-to-weight-to-weight ratio (ORR), a mean-to-weight-to-weight-to-weight-to-weight-to-weight ratio (CIVR) of patients with a mean-to-weight-to-weight-to-to-weight-to-to-to-to-weight ratio (CUC).",
      "start_page": 56,
      "end_page": 58
    },
    {
      "heading": "ADENOSARKOMA",
      "text": "IV adenic acid, which is a benign follow-up of , and from a mesencholine-recombination of 6 days of dosed dosed at a dose of 12.5 mg/day to a dose of 12.5 mg/day. Adenic acid, which is dosed at a dose of 12.5 mg/day, can be administered at a dose of 12.5 mg/day at a dose of 12.5 mg/day.",
      "start_page": 59,
      "end_page": 60
    },
    {
      "heading": "2. Other proposed combinations(all class 2B according to NCCN):",
      "text": "i. Fulvestrant ii. Megestrolacetate iii. Medroxyprogesteroneacetate iv. GnRHanalogs Meri expre Onco ic-Bernstam F, Ma essing solid tumo biology Annual Mee akker V, Oaknin A, et al. Efficiency and safety of trastumuYors:",
      "start_page": 60,
      "end_page": 65
    },
    {
      "heading": "C53, C53.0, C53.1, C53.8, C53.9",
      "text": "Human papillomavirus (HPV). Inoculation, against subtypes of HPV, does not negate the current The treatment plan followed in early-stage FIGO patients (IA, IB1 and IIA 4 cm) [3] i. either radical hysterectomy (with or without adjuvant radiotherapy) ii. or radical chemoradiotherapy with Cisplatin 40 mg/m2 weekly along with radiotherapy",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "Complementary Romanic (adjuvant) chemoradiotherapy after hysterectomy",
      "text": "Iv. in deep stromal filtration (1/3), no matter the size of the tumor ii. no more patients of the stage irradiation than the stage irradiation (1/3), no more patients of the stage irradiation (1/3) with a tumor size of >2 cm B. tumor size of >4 cm and in the deep or intermediate stromal filtration (1/3) A. Positive pelvic lymph nodes [pN1]\n\nKEYNOTE-A18 study the addition of pembrorizumab (200 mg IV Q3W  5 cycles and 400 mg IV Q6W  15 cycles) to chemo-radiotherapy (cisplatin 40 mg/m2 IV QW for 5 or 6 weeks + EBRT followed",
      "start_page": 66,
      "end_page": 68
    },
    {
      "heading": "CI, 61.8-73.0) vs. 57.3% (95% CI, 51.2-62.9) of disease-free patients at 24 months; HR 0.70 (95%)",
      "text": "IV, 0.55-0.89) P = 0.0020) [24]. The FDA has given an option for the combination, while approval from EMA is pending. Cisplatin 50 mg/m2, day 1, IV + Topotecan 0.75 mg/m2, day 1-3, IV alone with cisplatin. Although the regimen is highly myelotoxic, with appropriate support no Ifosfamide 5 gm2.",
      "start_page": 68,
      "end_page": 69
    },
    {
      "heading": "3. Epirubicin",
      "text": "4.Cyclophosp hamide",
      "start_page": 69,
      "end_page": 69
    },
    {
      "heading": "5. Ifosfamide",
      "text": "6. 5-Fluoricil Paclitaxel-free patients were treated with a dose-free dose of chemotherapy as a placebo-free combination of chemotherapy.Rubumab-free patients were treated with a dose-free, placebo-free, dose-free, dose-free, dose-free, dose-free, dose-free, dose-free, dose-free, placebo-controlled, dose-controlled, dose-controlled, dose-free, dose-free, dose-free, dose-free, dose-free.\n\nPatterns of cancer incidence, mortality, and prevalence across five contexts: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137-2150. doi:10.1200/JCO.2005.05.2308",
      "start_page": 69,
      "end_page": 71
    },
    {
      "heading": "C34, C34.0, C34.1, C34.2, C34.3, C34.8, C34.9",
      "text": "A. MICROCUTARY CANCER Pneumonoclavin+patients' total survival at dose-responsiveness at dose-responsiveness was demonstrated at dose-responsiveness at day-to-day ciplatin/etopolside at day-to-day ciplatin/etopolside at day-to-day ciplatin/etopol.\n\nCarboplatin AUC 56 or Cisplatin 7580mg/m , day 1 + ectoplasmic disease response 80100mg/m , days 13+ Durvalumab 1500mg, day 1 21-day cycles for 4 cycles and then maintenance therapy with Durvalumab 1500mg, day 1 every 3. Cisplatin 7580mg/m , day 1+Etoposide 80100mg/m , day",
      "start_page": 73,
      "end_page": 76
    },
    {
      "heading": "1. Topotecan",
      "text": "1.5 mg/m2, days 1-5, IV",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "or Topotecan",
      "text": "1,3 mg/m2, days 1-5, P.O. 2, CKyaclhoep 2h1o treated cycles 4 mg/m2 IV, days 4 mg/m2 IV, days 4 mg/m2 IV, days 4 mg, days 4 mg/m2 IV, days 4 mg, days 4 mg/m2 IV, days 4 mg/m2 IV, days 4 mg/m2.",
      "start_page": 76,
      "end_page": 80
    },
    {
      "heading": "B.2. COMPLETE (ADJUVANT) TREATMENT",
      "text": "0.00 patients with N1 disease, N2 [4]. Most patients were treated on the basis of virorelMumab-comparative therapy; cisplatin-comparative patients were treated with cisplatin-comparative therapy; cisplatin-comparative patients treated with cisplatin-comparative therapy; cisplatin-comparable patients with ci-comparable ci-compar-compar-compar-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-compoin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-composin-com\n\nPembrolizumab was approved by the EMA as adjunctive therapy in patients with a high risk of relapse [stage IB (T2a  4 cm), II or IIIA according to the 7 version of UICC/AJCC] following a complete platinum-based exemption and chemotherapy, regardless of PD-L1 expression status in the tumour. The approval was based on the study KENOTE-091, in which .",
      "start_page": 80,
      "end_page": 81
    },
    {
      "heading": "Recommended treatment regimens adjuvant treatment",
      "text": "1. Cisplatin 100 mg/m2, day 1, IV + Vinorelbine progression 30 mg/m2, day 1, 15, IV every 28 days, 4 cycles (ANITA) 2. Cisplatin 50 mg/m2, day 1, IV + Vinorelbine at day 1, 15, IV every 28 days (JBR-10) 3.\n\nIV administered chemotherapy should be platinum-based. Therapy with carboplatin at day 1, at day 1, at day 1, at day 1, at day 1, at day 1, at day 1, at day 1, at day 1, at day 2, at day 1, at day 2, at day 1, at day 2, at day 2, at day 1, at day 2, at day 2, at day 2, at day 2, at day 2, at day 2, at day 2, day 2, day 4, day 4, at the same day 4, at the same day 4, at the same day 4, at the same day 4, at the same time.\n\nThe approval was based on the EMPOWER-Lung 1 study, which compared the efficacy of cemipumab versus chemotherapy1 to a dose of 350 mg per 3 weeks with the onset of disease progression. In the population with known PD-L1  50%, there was a 43% (HR: 0.57; 0.42; p=0.0002) reduction in risk with an extension of chemotherapy [mean survival].\n\nCemiplimab 350 mg IV per 3 weeks, up to disease progression or occurrence unacceptable - in combination with platinum-based chemotherapy in patients with PD-L1  1%, or - alone in patients with PD-L1  50%, NGS), in tissue (preferred biological material), or with liquid biopsy as long as either tissue or py inhibitors are not available. In patients with squamous carcinoma and py%",
      "start_page": 81,
      "end_page": 85
    },
    {
      "heading": "B.4.1. SYSTEM CHEMOTHERAPY OF FIRST LINE",
      "text": "EFR- / ALK-/ BRAF-/ROS1-negative combination of cisplatinic quintets with PS 0-2 that do not exhibit significant comorbidity. In patients with general condition index (PS) 0-1 the choice therapy is the combination of two cytostatics that have potency and indication in the cisplatin, carboplatin, docetaxel, paclitaxel.",
      "start_page": 86,
      "end_page": 87
    },
    {
      "heading": "Vinorelbine/Cisplatin",
      "text": "Vinorelbine Cisplatin Gemcitabine/Cisplati Gemcitabine Cisplatin",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "Docetaxel/Cisplatin",
      "text": "Docetaxel Cisplatin",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "Pemetrexed/Cisplatin",
      "text": "Pemetrexed Cisplatin",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "Etoposide/Cisplatin",
      "text": "Etoposide Displatin xed dplat21 mg dplatq2 base of cisplatin/gemcitabine in patients with theta the cisplatin/gemcitabine combination of 75 mg dplatin/ Dplatq2 mg dplatin/dplatin is not indicated in carboplatin over the paclitaxel/carboplatin combination as to the n 25mg/xed combination.",
      "start_page": 87,
      "end_page": 89
    },
    {
      "heading": "Docetaxel/Gemcitabine",
      "text": "Docetaxel 100 mg/m2 D8, q21d Gemcitabine 1100 mg/m2 D1.8, q21d",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "Paclitaxel/Gemcitabine",
      "text": "Paclitaxel 200mg/m2 D1, q21d Gemcitabine 1000 mg/m2 D1,8, q21d",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "Paclitaxel/Vinorelbine",
      "text": "Paclitaxel 135 mg/m2 D1, q15d Vinorelbine 25 mg/m2 D1, q15d",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "Gemcitabine/Vinorelbine",
      "text": "1000 mg/m2 D1.8, q21d Gemcitabine 25 mg/m2 D1.8, q21d Vinorelbine",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "Patients with General Status Index (PS) 2",
      "text": "Chemotherapy prolongs survival and improves the quality of life in patients with PS 2 in association with treatment-combined combination therapy with PS2, after discussion and updating of A randomised phase III study argues that the combination of carboplatin/pemetrexed offers a significant survival benefit over pemetrexed alone as a first-line treatment in patients with a chemotherapy marker with carboplatin significantly improves survival with respect to chemotherapy in patients with PS2 in association.\n\nElderly patients with PS 0-1 and selected patients with PS 2 are recommended to take Patients with PS 2 due to comorbidities, have a higher chance of developing adverse Carboplatin AUC 6, D1 q28d in combination with Paclitaxel 90mg/m2, d1, 8, 15 per q28d Carboplatin AUC 6, D1, q21d in combination with Nab-paclitaxel 100mg/",
      "start_page": 89,
      "end_page": 91
    },
    {
      "heading": "Bevacizumab",
      "text": "In the randomised phase III study ECOG 4599, bevacizumab improved overall survival in combination with paclitaxel/carboplatin in patients with PS 0-1 alone and may be administered to patients with non-plateletic MMCP who show no contraindications to the use of bevacizumab. The randomised AVAiL study, which examined bevacizumab in combination with gemcib",
      "start_page": 91,
      "end_page": 92
    },
    {
      "heading": "AVAiL",
      "text": "1 Cispla Gemc Bevac Day2 1 mg Day dmq2 Day; 15mgq2 mg Day dmq2; 15mgq2 dmq2 dmq2 dmq2 dmq2 dmq; 75bq Bevac Point laclit Carbo Bevac Point Carbo Peme Bevac G 4599 taxel oplatin cizuma L atin cizuma PERL atin etrexed cizuma tBreak",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "CHEMOTHERAPY OF CONSERVATION (MAINTENANCE)",
      "text": "(continuation maintenance), usually of non-platinismorex treatment; treatment-responsive treatment-responsive therapy with treatment-responsive therapy at baseline (responsive therapy) with treatment-responsive therapy (responsive chemotherapy) at baseline; treatment-responsive therapy-responsive therapy (responsive chemotherapy) at baseline. The phase III PARAMOUNN showed that administration of pemetrexed and erib as a ‘switch mainline.\n\nNote: It is also recommended that maintenance therapy with cemiplimab-rwlc mediated PMRID1-relaxed PMRID1-relaxed PMRID1-relaxed patients with no PPMID-relaxed PPMID1 and no PPMID-relaxed PPMID1-relaxed patients have the PPMID-relaxed PPM1 response to PPMID2. In patients who did not show progression of the first line of PPM1 in line of PPM1 patients with platinum Erlotinib 150 mg-r.\n\nIn the study IMpower 110, patients were randomised to receive either atezolizumab 1200 mg every 21 days with worsening of the disease or atezolizumab versus 14.3 months for chemotherapy in patients with high PD-L1 expression (HR: 0.52). The administration of cemiplimab, a fully human immunoglobulin antibody G4 (IgG4) is also approved by the EMA.\n\nThe data relate to a population with squamous and non-placular PDAB1 patients were shown to be at baseline at baseline at baseline of CEMVOC at 1 mg, intravenously, per 3 weeks, or 840 mg intravenously at 2 weeks, or 1680 mg Cemiplimab at 350 mg, intravenously, per 3 weeks, to progression of the disease.\n\nALB therapeutic regimen: Cemiplimab 350mg, intravenously, within 30 minutes, per 3 weeks, to progression of disease or occurrence of PD-L1 The addition of Pembrolizumab to chemotherapy with Carboplatin and Pemetrexed and subsequently maintenance therapy with Pemetrexed and Pembrolizumab, is recommended by the EMA in patients.\n\nEMA-administered combination of Carboplatin/Paclitaxel versus nab-Paclitaxel (Paclitaxedumab-recombinant dosed at a dose of 0.05-fold-on-week-on-week-on-week-on-week-on-week-on-week-on-week-on-week-on-week-on-on-week-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-on-\n\nPost-platinum chemotherapy: Durvalumab 1,500 mg dose Tremmoenliom aubmumab-free patients treated with a placebo-free combination of patients treated with a placebo-free combination of placebo-free chemotherapy. Patients treated with chemotherapy alone should be treated with a placebo at week 16 with Durvalumab. Pembrolizumab in patients with PD-L1>1% regardless of histological type, where the overall survival was 16.7 months versus 12.1 for chemotherapy (Keynote-04HR study).\n\nIn this study pembroizumab prolonged overall survival vs. chemotherapy progression, both at the dose of 2 mg/kg (mean survival of one year 43.2 vs. 34.6%, HR 0.71; 95% CI 0.08; p=0.0008) and at the dose of 10 mg/kg (HR 0.61; 95% CI: 0.49075).\n\nIn a retrospective analysis, it was shown that patients with non-platinous MRM were treated with a dose-responsive treatment of patients with a dose-responsive phase-responsiveness of a dose-responsiveness of 0.081.0, P = 0.004.\n\nAfatinib resulted in a decrease in the risk of relapsed patients by a combination of absorbide-to-responsive treatment of patients with absorbide, absorbide, absorbide, absorbide, and absorbide. Absorbide-to-responsive treatment of patients treated with absorbsorb.\n\nThe most common mutations of EGFR) are exonogenous exonogenous eliminations Texin-responsive eliminations of phase 19 (45% of the time) Texin-responsive eliminations, Texin-responsive eliminations of phase 2 patients, Texin-responsive eliminations of phase 2 patients, and TK-responsive mutation L857 (40% of cases). These mutations are correlated to Tyrosine kinase inhibitors (TK) and are referred to senetic mutations.\n\nThe increase in overall survival was also found in patients with elimination in exonium 19 and in patients with a dose-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive-responsive-responsiveness-responsiveness-responsiveness-responsiveness-responsiveness-responsiveness-responsiveness-responsiveness-responsiveness-res.\n\nIn a median follow-up of 22.0 months, amivantanb plus lazertinib showed a 30% decrease in the risk of progression of the disease versus death compared to ossi (HR, 0.70; 95% CI, 0.58-0.85; P0.001), with a median PFS of 23.7 months (95% CI, 19.1-27.7) compared to 16.6 months (95% CI, 14.8-18.5).\n\nCaution is required for administration of TP inhibitors of EFR in patients who have previously been exposed to immunocompromised immunocompromised immunomodulators (RACs), as in those who received durvalumab after concomitant chemoradiotherapy as maintenance therapy in stage III disease or because the EFR mutation status was osimertinib for at least three months after the completion of immunotherapy, in order to avoid increased toxicity associated with TP inhibitors.\n\nEGF FR, suggested the incorporation of Erlotinib 150 mg/day dosed intravenously at 1 mg/day dosed at 1 mg/day dosed at 1 mg/day dosed at 1 mg/day dosed intravenously at 1 mg/day dosed at 1 mg/day dosed at 1 mg/day dosed at 1 mg/day dosed at 1 mg/day dosed at 1 mg/day dosed at 80 mg/day at 100 mg/day at 150 mg/day at 150 mg/day at 100 mg/day at 100 mg/day.\n\nThe subgroup of patients with its translocation is highly susceptible to the corresponding TP inhibitors; crizotinib-responsive therapy was associated with the first-stage treatment of CK-responsive therapy; crizotinib-responsive therapy was associated with the CK-responsive treatment of CK-responsive therapy; crizotinib-responsive treatment with the combination of CK, ROS1 and MET patients with CK-disponsive distribution.\n\nCeritinib has been approved by the EMA as first-line treatment of adults with ALK-responsiveness; CIlectib-responsiveness was not achieved in ALK-responsiveness patients; ALK-responsiveness was not achieved in ALU-responsive treatment; ALU-responsive treatment was not achieved in ALU-responsive treatment.\n\nIn the final analysis of the ALTA 1L study the mean follow-up time for brigatinib was 40.4 months versus 15.2 months in the crizotinib arm; brigatinib demonstrated an improvement in PFS versus crizotinib, significantly reducing the risk of disease progression or death by 51% (hazard ratio [HR]: 0.48 [95% CI: 0.35-0.66, P0.0001]).\n\nAdenocarcinoma-responsiveness of adenocarcinoma) lung is recommended to be tested for the presence of ALK-dissociation-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive phase-responsive-responsive phase-responsive phase-responsive phase-responsive-responsive-restable phase-responsive-responsive-responsive-responsive-responsive-resonsive-restable-restable-restable-restable-restable-restable-restable-restable-restable-resive-restable-responsive-responsive-restable-resive-restable-resive-resive-restable-resonsive-restable-restable-restable-resive-restable-restable-restable-restable-responsive-responsive-resive-restable-restable-responsive-restable-responsive-restable patients-restable-restable-restable-restable-restable-restable-restable-restable-restable-restable-restable-restable-restable-restable-responsive-restable-restable-responsive-responsive-restable-responsive-resive-responsive-responsive-restable-restable-restable-restable-restable-restable-restable-restable-restable-restable-restable-responsive-restable-restable-restable-restable-re\n\nOral approval was based on pooled results of 53 patients with ROS1 positive MMP, overall response response response response response was demonstrated by 62% at baseline with a median response duration of 25 months and median PFS 19 months. patients [6 months, date of collection (cut-off) of clinical data 01-May-2019] confirms the significant clinical benefit of Entrectinib in patients with a fusion-positive ROS1 MMP].\n\nInhibition of BRAF with micromolecular inhibitors (vemurafenib, dabrafenib) treatment treated patients with a dose-positive combination of BRAFV600-positive NSCLC treated patients with a dose-positive combination of BRAF inhibitor dabrafenib and MEK inhibitor trametinib showed an objective response of 63.2% [95% CI 49.375.6] to patients with BRAFV600.",
      "start_page": 93,
      "end_page": 111
    },
    {
      "heading": "Patients with RET rearrangements",
      "text": "The adult rearrangements of the RET gene, a transmembrane protein dosed at a pre-responsive dose of PBIT, and the dose-responsive dosed dose-responsive response of PBIT patients with a pre-responsive dose of PBIT to the tissue homeostasis rate of PBIT patients has been examined in the LIBRETTO-001 study with responses reaching 64% in pre-treated measurable disease, with 23% of patients.\n\nThe patients treated at baseline were treated at a baseline of 42% at baseline of 42% at baseline.42% at baseline of 42% at baseline were treated with 42% at baseline.42% at baseline 42% at baseline 44% at baseline.42% at baseline at baseline 42% at baseline.42% at baseline at baseline.42% at baseline.42% at baseline at baseline.\n\nThe approval by the EMA concerns the next According to the results of the study CHRYSALIS (phase 1 receptor therapy/coagulation receptor therapy), the treatment-associated patients with the combination therapy of the combination therapy with the combination therapy of the combination therapy of the two-stage therapy of the two-stage therapy with the combination therapy of the two-stage therapy of the two-stage therapy of the two-stage therapy. The clinical benefit rate of the drug was 21% (ORR)\n\nThe approvals were based on an analysis of 3 phase I/II studies that infused patients with quinogenic quinogenic quinogenic quinogens with quinogenic quinogens with quinogenous quinogenic quinogens with quinogenic quinogenic quinogens with quinogenic quinogens with quinogenic quinogens with quinogens that did not have a 79% response rate, Entrectinib for patients with ROS1 mutations1 mutations, has also received approval from EMA and FDA and FDA and FDA assays assay patients.\n\nActivated KRAS mutations, seen in about 20/ 25% of patients treated with adenocarcinomas parsopreceptors spersed lung/generally associated with smoking. Strategies targeting KRAS G12C mutation which makes up about 50% of KRAS mutations in the MMCP or molecules that are under the activated RAS. Sotorasib is a micromolecular inhibitor that was tested",
      "start_page": 112,
      "end_page": 116
    },
    {
      "heading": "ASSOCIATIONS WITH EFR TRANSLATIONS",
      "text": "Most patients with TEFR mutations have developed progression of the disease after approximately 913 months of treatment with a second-generation mutation with erlotinib; gefitinib or afatinib. Treatment of these patients depends on whether it is local therapy; osimertinib (confirmed T790M mutation) or systemic administration of the T790M mutation is implicated in the exon 20 EGF.\n\nERIPOSA-2 is a randomised, open-label phase 3 study that evaluates the efficacy and safety of two regimens of amibantamab (with and ω1i6i in lazertinib) patients with locally advanced or metastatic MMCP with EGFR ex19del or L858R substitution that had progression of the disease with or after osimertinib has been examined.\n\nThe median progression-free disease survival (mPFS) was 8.3 months (95% CI, 6.5 to 10.9) and the median overall survival (mOS) of the first-responsive-responsive-responsive-responsive-responsive-responsive-responsive-to-responsive-responsive-to-responsive-responsive-to-respirator patients TFRF.\n\nThe combination of chemotherapy, immunotherapy, and anti-VEGF treatment patients ALIMCIDs were pre-responsively treated with ALIMCIDs at a pre-responsive dose with ALIMCIDs at a post-responsive dose of ALIMCIDs; ALIMCID patients with ALIMCIDs at a pre-responsive dose of ALIMCIDs were treated with ALIMCIDs.\n\nHowever, brigatinib has been associated with early-onset treatment of ALK-responsive chemotherapy. A new generation of ALK- or ROS-1-responsive chemotherapy patients can be treated with at least one ALK-responsive treatment. ALB-responsive therapy patients with at least one ALK-responsive therapy may not be treated with ALB-responsive therapy.\n\nThe combination of chemotherapy, immunotherapy, and anti-VEGF therapy is recommended only when patients Ceritinib-responsive leukemia syndrome (B.M.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R. is approximately 750 mg per day. with the progression of the disease or non-A.A.A.R.R.R.R.R.R.R.R.R.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C\n\nTaking into account that platinum combinations with pemetrexed have resulted in improved radiotherapy combination therapy with a 3D-CRT or IMRT treatment regimen for improvement of local-regional disease control, in particular FDA and EMA approved the ipilimumab/nivolumab immunotherapy combination, as in a phase III study (CHECKMATE 743), in the 1 line of treatment, nivolumab was given.",
      "start_page": 116,
      "end_page": 134
    },
    {
      "heading": "2) Epithelioid histological type",
      "text": "Patients with epithelials unresectable mesothelioma were advised to receive a treatment-preparation combination of 95% chemotherapy compared to 95% chemotherapy (ipilimumab/ nivolumab) or cisplatin/pemetrexed according to the results of the CHECKMATE 743 study. The mean total survival in the immunotherapy arm was 18.7 months versus 16.5 months in the chemotherapy arm, a difference not statistically significant (HR=0.86)",
      "start_page": 134,
      "end_page": 135
    },
    {
      "heading": "4) Alternative options",
      "text": "The combination of pemetrexed, cisplatin, and pemproxumab dosed at a baseline of cimetrexed/ cimetrexed at a dose of cimetrexed/ cimetrexed/ cimetrexed/ cimetrexed/ cimetrexed at a dose of cimetrexed/ cimetrexed patients at a dose of cimetrexed patients.\n\nThe combination of ipilimumab/nivolumab in the 2 mg treatment line in patients with platinum-resistant pempromix + pempromix arm + placebo-free days showed an improved objective response compared to gemcitabine or vinorelbine (22% vs.6%) with no statistically significant difference in progression-free disease interval (PFS 2.5 vs 3.4 months) as well as total survival (OS 10.7 vs 11.7 months)\n\nPembrolizumab 200 mg in 21-day cycles 8. Nivolumab 240 mg treated with adjuvant bilirubin as adjutant in patients treated with adjutant bilirubin. in patients treated with adjutant bilirubin. in patients treated with bilirubin, in patients treated with bilirubin, in patients treated with bilirubin, in patients treated with bilirubin.",
      "start_page": 135,
      "end_page": 143
    },
    {
      "heading": "CAP:",
      "text": "cisplatin 50 mg/m + doxorubicin 50 mg/m + cyclophospamide 500 mg/m day 1, in cycles 21 CmAePr + ω π πο ποοο: cisplatin 30 mg/m days 1-3 + doxorubicin 20 mg/m day 1-3 + cyclophosphamide 500 EmPg:/m day 1",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "Pembroizumab",
      "text": "200 mg per three weeks, only in thymic carcinoma, to disease progression, Etoepmofsiadneis:the unacceptable toxicity or maximum for 2 years. Ifosfamide :days 13 emetoside 120mg/m , every 3 weeks to 8 cycles Pemetrexed h:days 15 Ifosfamide 1.5g",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "(including LAR)  prednisone: Octreotide 0.5 mg Y.D. TID  Prednisone 0.6",
      "text": "5-FmU g+/ lkegu/cdoavis rhoin: 1-day Cplaticulture Cpl.15mg/day Cpl.Cpl.15mg/day Cpl.Cpl.15mg/day Cpl.Cl.15mg/day Cpl.Cl.15mg/day Cpl.Cl.15mg/day Cpl.\n\nIV diagnosing ICD-10: C15, C15.0, C15.2, C15.3, C15.4, C15.8, C15.9 5 FUcisplatin + Radiotherapy Cisplatin 75mg/m2, day 1, IV + 5FU 1000mg/m2, days 15, IV Every 28 days, 4 cycles, along with radiotherapy 50, 4 cycles, C15.8, C15.9\n\nDiagnose ICD-10: C15, C15.0, C15.2, C15.2, C15.4, C15.8, C15.9 ECF Epirubicin 50mg/m2, day 1, IV + Cisplatin 60mg/m2, day 1, IV + 5200mg/m2 24 hour IV infusion without interruption, day 121 ECX\n\nFor Paclitaxel 8090 mg/m2 iv infusion of 1-hour infusion of Irinodex/300 mg/m2 at day 1, IV, IV, IV, IV, IV, IV, and IV.\n\nIVroforminib PO, 100mg, twice daily, day-to-day administration of Entremictibrexedopreceptors (C.P.R.R.R.C.R.R.C.R.C.R.C.R.C.C.R.C.R.C.R.C.R.C.R.C.C.C.R.R.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C\n\nNote 2: A newer anti-HER2 agent, Trastuzumab Deruxtecan, which belongs to the class of monoclonal antibody-drug (ADC) conjugation medicinal products, has received ‘breakthrough therapy design' and ‘orphan drug design', received official FDA approval in January 2021 for the treatment of patients with unresectable or metastatic HER2-theoretic (HER2-theoretic)\n\nECF Epirubicin 50mg/m2, day 1, IV + Cisplatin 60mg/m2, day 1, IV + 5FU 200mg/m2 24 hour infusion IV without interruption, day 121 ECX Epirubicin 50mg/m2, day 1, IV + Cisplatin 60mg/m2, day 1, IV + Capecitabine 1000 mg/m2 twice daily, EOX Epirubicin 50mg/m2 day\n\nDIGNIZING ICD-10: C16.0 as C16.2, C16.8, C16.9 days of topically advanced or metastatic, unresectable stomach cancer (adenocarc ECF Epirubicin 50mg/m2, day 1, IV + Cisplatin 60mg/m2, day 1, IV + 5FU 200mg/m2 24 hour infusion IV without interruption, day 1-21 ECX Epibicin 50mg/m2\n\nNote 2: Chemotherapy is only recommended for patients with ECOG performance status 2. In elderly patients and in patients with performance status 3-4 days each day use 5-FU regimens (such as De Gramon) or supportive treatment only. (FAM, FAMTX, EAP etc.) have been used in previous decades but today their use is not recommended, both because they have been shown to be less effective than ECF and due to adverse effects.\n\nIvbrobumab 200mg, day 1, IV Pembrobromizumab 400 mg, day 1, IV immunosuppliers + sympathochemical expression of DNA repair proteins (mismatch repair, MMR) or high TMB (Tumor Mutual Burden), limit TMB 10 mut/Mb), as determined by the NGS platform FoundationOne CDx assay (or by other valid platforms)\n\nNote 2: A newer anti-HER2 agent, Trastuzumab Deruxtecan, which belongs to the class of monoclonal antibody-drug (ADC) conjugation medicinal products, has recently received \"breakthrough therapy design\" and \"orphan drug design\" from the FDA for the treatment of patients with inoperable or metastatic HER2-positive (IHC 3+ or IHC 3+).",
      "start_page": 144,
      "end_page": 170
    },
    {
      "heading": "Gemcitabine:",
      "text": "1000 mg/m2, days 1, 8, 15 , IV Capecitabine plus gemcitabine Capecitabine 830mg/m twice daily D1-D Gemcitabine1000mg/m IVdays 1, 8, 15 , IV",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "Modified FORFIRINOX",
      "text": "Oxaliplatin 85mg/m IV D1 Leucovorin 400mg/m IV D1 Irinotecan 150mg/m IV D1 Fluorouracil2,400mg/m IV in 46 hours injection D1- Gemcitabine 1000 mg/m2, each week, for 3 weeks continuous administration of 5FU (225 mg/m2 24-hour intravenous Gemcitabine (1000 mg/m2)",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "FOLFIRINOX",
      "text": "Oxaliplatin 85mg/m IV D1 Leucovorin 400mg/m IV D1 Irinotecan 180mg/m IV D1 Fluorouracilc 400mg/m IV D1 IV bolus Fluorouracil 2,400mg/m IV in 46 hours injection D1-D2",
      "start_page": 179,
      "end_page": 179
    },
    {
      "heading": "Modified FOLFIRINOX",
      "text": "Oxaliplatin 85mg/m IV D1 Leucovorin 400mg/m IV D1 Irinotecan 150mg/m IV D1 Fluorouracil 2,400mg/m IV in 46 hours injection D1-D2 Gemcitabine plus nab-paclitaxel Gemcitabine: 1000 mg/m2, days 1, 8, 15 , IV Nab-paclitamg",
      "start_page": 179,
      "end_page": 179
    },
    {
      "heading": "NALIRIFOX",
      "text": "Liposomal Irinotecan 50 mg/m2 Oxaliplatin 60 mg/m2 Leucovorin 400 mg/m2 5-FU 2.400 mg/m2 This regimen was examined in the Napoli 3 study and showed statistically significant and clinical benefits in total survival and progression-free survival of the disease (FDA approved & EMA submitted).",
      "start_page": 179,
      "end_page": 180
    },
    {
      "heading": "Gemcitabine",
      "text": "1000mg/m2, days 1, 8, 15, IV, after \"charging\" with 7 consecutive weeks of treatment",
      "start_page": 180,
      "end_page": 180
    },
    {
      "heading": "Gemcitabine 1000mg/m2, IV + Cisplatin 50mg/m2, days 1, 15, IV",
      "text": "with BRCA 12 or PALB2mutations",
      "start_page": 180,
      "end_page": 180
    },
    {
      "heading": "Gemcitabine",
      "text": "Erlotinib 1000mg/m2, days 1, 8, 15, IV, after prior \"charge\" with 7 consecutive weeks of treatment and 1 week stop + (Tarceva) 100 mg daily continuously, PO",
      "start_page": 180,
      "end_page": 180
    },
    {
      "heading": "Liposomal Irinotecan 70 mg/m intravenously over 90 minutes, followed by Leucovorin",
      "text": "400 mg/m intravenously over 30 minutes, followed by 5-FU 2,400 mg/m intravenously on fluorouracil (5-FU) and leucovorine (LV), in adult patients who have progressed after oxaliplatin or irinotecan (FOLFOX, FOLFIRI, OFF)",
      "start_page": 180,
      "end_page": 180
    },
    {
      "heading": "OFF Figure",
      "text": "IVucovorin (200 mg/m ) recommended by 5-FU (2,000 mg/m2 in 24 hour continuous infusion on days 1, 8, 15, and 22 and oxaliplatin (85 mg/m on days 8 and 22) treatment alternatives for patients with MMR deficiency-MSI Pembrolizumab 200mg IV, 1 day (85 mg/m on days 8 and 22).",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "For patients with NTRK fusion",
      "text": "Larotrectinib 100mg daily 2 times a day (EMA & FDA approved) Entrectinib 600mg once a day (EMA & FDA approved) For patients with BRAF V600E mutations there are satisfactory alternative treatment options. (Under FDA accelerated approval) Dabrafenib + Trametinib Dabrafenib 150mg PO twice daily Trametinib 2 mg PO once daily For patients",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "For patients with germline BRCA 1/2 mutations",
      "text": "1000 mg platinum-based chemotherapy without worsening of disease (EMA & FDA-approved) Olaparib 300 mg once daily dosed patients at 1, pemvastatin + 1 mg once daily dosed patients at 1,if there are no contraindications to their administration.Oxaliplatin Should be administered without specific justification under the FOLFIRINOX or GemOx regimen. in NCCN's guidelines (17).",
      "start_page": 182,
      "end_page": 190
    },
    {
      "heading": "For patients with high TMB (Tumor Mutational Burden)",
      "text": "Pembrolizumab 200mg, day 1, IV Pembrolizumab 400 mg, day 1, IV For patients with high TMB (Tumor Mutual Burden, TMB limit 10 mut/ by NGS platform FoundationOne CDx assay (or by other valid pl treatment options (FDA approved).",
      "start_page": 190,
      "end_page": 190
    },
    {
      "heading": "For patients with NTRK fusion",
      "text": "Larotrectinib 100mg 2 times a day (FDA & EMA approved) Entrectinib 600mg once a day (EMA & FDA approved) pero, for 14 days, PO rated approval) /Mb), such as this ad",
      "start_page": 190,
      "end_page": 190
    },
    {
      "heading": "For patients with FGFR2 fusion",
      "text": "Pemigatinib alone is indicated for the treatment of adults with locally advanced or growth factor 2 (FGFR2) that has progressed after at least one previous line The recommended dose is 13.5 mg Pemigatinib taken once daily for 14 days, with an interval of 7 days out of treatment. (FDA & EMA approved). Futibatinib alone with Futibatinib is indicated for treatment",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "Ivosidenib alone is indicated for the treatment of adult patients with locally advanced",
      "text": "metastatic cholangiocarcinoma with an IDH1 R132 mutation, which were pre-supplied",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "The recommended dose is 500 mg Ivosidenib (2 x 250 mg tablets) taken orally once daily.",
      "text": "by the patient. ( FDA &, EMA approved ) For patients with BRAF V600E mutations Dabrafenib + Trametinib there are satisfactory alternative treatment options. (Under FDA accelerated approach) Dabrafenib 150mg PO twice daily Trametinib 2 mg PO once daily",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "For patients with RET fusions",
      "text": "Selpercatinib satisfactory alternative treatment options. (Under FDA accelerated approv If SB  50 kg: 120 mg PO twice daily If SB >50 kg: 160 mg PO twice daily The combination of Gemcitabine/ Cisplatin has given survival advantage to random denosumab/months, since there are no contraindications to their administration as well. val viruses) of the hepatitis type",
      "start_page": 192,
      "end_page": 197
    },
    {
      "heading": "local control of the disease etc. In the systemic treatment arm the administration of Sorafenib to patients with",
      "text": "good general condition (0-2 against ECOG) and Child-Pugh score A has been shown to improve survival of ICD-10 Diagnosis:",
      "start_page": 197,
      "end_page": 197
    },
    {
      "heading": "Sorafenib",
      "text": "Sorafenib 400 mg morning and 400 mg evening daily",
      "start_page": 197,
      "end_page": 197
    },
    {
      "heading": "Lenvatinib",
      "text": "60 kg: 8 mg PO daily 60 kg: 12 mg PO daily",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "Atezolizumab plus bevacizumab",
      "text": "Atezolizumab 1200 mg BKaevthaec 2iz1u μmaebre 15 mg/kg αTrethmeneolinm kuami satbo syfsn. durvalumab Durvalumab in combination with Tremelimumab indicated HIMALAYA. Durvalumab 1,500 mg administered in combination with Tre D1/ durvalumab",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "Regorafenib",
      "text": "160mg PO D1-D21",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "Cabozantinib",
      "text": "60 mg PO",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "Ramucirimab",
      "text": "8mg/kg IV in patients with aFP400 ng/ml IMbrave 150 offered a benefit of surviving emelimumab 300 mg as a single dose of f",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "Nivo umab ipilimumab",
      "text": "Combination of 1mg/kg and 3mg/kg every 3 weeks for 4 doses followed by administration of 240 mg of Novolumab every 2 weeks (FDA approval) nivolumab as alone or in combination with ipilimumab is indicated for adult patients with hepatocellular carcinoma who received sorafenib at a previous treatment line. The indication has been approved by the FDA as accelerated approval based on the overall rate and duration of apne",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "For patients with NTRK fusion",
      "text": "Larotrectinib 100mg 2 times a day (EMA & FDA approved) Entrectinib 600mg once a day (EMA & FDA approved)",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "For patients with RET fusions",
      "text": "satisfactory alternative treatment options. (Under FDA accelerated approval) Selpercatinib If SB  50 kg: 120 mg PO twice daily If SB >50 kg: 160 mg PO twice daily Doxorubicin 60mg/m2, day 1, IV Every 21 days",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "GEMOX",
      "text": "Gemcitabine 1000mg/m2, day 1, IV + Oxaliplatin 100mg/m2, day 1, IV",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "FOLFOX",
      "text": "Oxaliplatin 85mg/m D1 Leucovoretinal carcinoma S1 5mg/m D1 FU 400 mg IV bolus D1 5 FU 2400mg/m2 in continuous infusion 48 hours of denosumab/month. Notation 2: Regarding immunotherapy, Tremelumab, an anti-CTLA4 inhibitor, recently received \"orphan drug design\".\n\n37.El-Khoueiry AB, Sangro advanced Cavitational solvents 20; Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):",
      "start_page": 200,
      "end_page": 207
    },
    {
      "heading": "Chemotherapy with FOLFOX or CAPTEM: mainly in tumors with Ki 67>15%",
      "text": "C25, C25.0, C25.1, C25.2, C25.3, C25.3, C25.7, C25.8, C25.9 Somatostatin analogues for cases of G1, G2, good and moderate streptozocin 500mg/m IV/d + 5FU 400mg/m IV/d for 5 days every 6 weeks Capecitabine (750 mg/m2 twice daily, 150 mg/m2)",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "FOLFOX",
      "text": "2020 Eradicumus 10 mg P.O. daytime oxicinate Cplatinib 37.5 mg P.O. daytime oxicinate Cplatinic Cplatinic Cplatinic Cplatinic Cplatinic Cplatinic Cplatinic Ctopinic Ctopinics and C37 Everolimus 10mg/day Assay somatostatinin receptors G1, mide G2 mg/m m2 once C34, C34.0, C34.2, C34.2, C34.2, C34.2, C34.2, C3.2, C34.3, C3.2, C34.3, C34.2, C3.3, C34.2, C3\n\nDiagnosis ICD-10: C18, C18.0, C18.1, C18.2, C18.4, C18.7, C18.8, C19, C20 en ru stadium II high-risk mind (from clogging, to passing, the T4 gous, grade 3, exc.",
      "start_page": 207,
      "end_page": 213
    },
    {
      "heading": "FLOX",
      "text": "IVdoplatin 85 mg/m , day 1, 29, IV + Leucovorin 250 mg/ + day 1, 15, 29, 36 IV bolus Mayo Clinic Regimen 525 mg/m , day 1-5 + Leucovorin 500 mg/m , day 1 + Leucovorin 20 mg/m , day 1 , day 2 .\n\nAdministration of CFU in 24th rs IV injection 750-1000mg/m . , for 5 days complete chemotherapy with either the 1st and 5th week of administration of Capecitabine at dose 825mg/m twice daily as PO daily 5 days at weekda, at all times according to recent published reports of RA studies\n\nIV: 400 mg ochres ochres ochres ochres ochres  400 mg ochres ochres ochres ochres ochres  400 mg ochres ochres ochres ochres ochres  400 mg ochres ochres ochres  1, C18.7, C19, C20, C20, C20 Roswell Park  500 mg/m ochres ochres ochres ochres",
      "start_page": 213,
      "end_page": 218
    },
    {
      "heading": "We amend no FOLFIRI",
      "text": "Iritotecan 180 mg/m , day 1, IV + Leucovorin 400 mg/m , day 1, in a two-hour IV fortification, followed by a 5FU 400 mg/m , day 1, IV bolus and then 5FU 2400 mg/m in IV fortification",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "FOLFIRI",
      "text": "Irinotecan 180 mg/m , day 1, IV + Leucovorin 200 mg/m , days 1, 2, in a two-hour IV tinnitus, followed by 5FU 400 mg/m , days 1, 2, bolus IV and then 5FU 600 mg/m (day 1.2)",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "FOLFOXIRI",
      "text": "Irinotecan 150-165 mg/m , wed 1, IV + Oxaliplatin 85 mg/m , wed 1, IV + Leucovorin 200 mg/m , wed 1, in 2-hour IV chyme, followed by 5FU 2400-3200 mg/m in IV chyme 48 hrs",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "FOLFIRINOX ACCORD",
      "text": "Irinotecan 150 mg/m , day 1, IV + Oxaliplatin 85 mg/m , day 1, IV + Leucovorin 200 mg/m , day 1, in 2-hour IV infusion, followed by 5FU 400 mg/m , day 1, IV bolus and follow th 5FU 2400 mg/m in IV injection\n\n400 mg oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz. oz.\n\nIROX Oxaliplatin 85 mg/m , IV + Irinotecan 200 mg/m , IV Irinotecan 300-350 mg/m IV, H with ra 1 UFT UFT 100 mg/m , for 28 with therres, morning-afternoon + Leucovorin 30 mg/m , for 28 days in the morning",
      "start_page": 218,
      "end_page": 222
    },
    {
      "heading": "1. Bevacizumab:",
      "text": "5  10 mg/kg and  2 weeks see  7.5 or 15 mg/kg and  3 weeks see",
      "start_page": 222,
      "end_page": 222
    },
    {
      "heading": "2. Aflibercept",
      "text": "4mg/kg in IV confusion and thorax 2 weeks see dosed dosed dosed dosed at FUbira dosed at FUbira dosed at FUbira dosed at FUbira dosed at FUbira dosed at FUbira dosed at FUbira dosed at molfibira dosed at 3. Cetuximab In patients with non-mutated RAS at go: 250 mg/m/m at week\n\nFAM-TRASTUZUMAB-DERIMXTECAN rifampicol rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifamp patients rifamp patients rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifamp patients rifampicin rifamp rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifamp rifamp rifampicin rifampicin rifampicin rifampicin rifamp rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifamp rifamp patients rifamp rifamp rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rifampicin rif\n\nDostarlimab -gxly for patients with tumors after previous treatment failure; however, since there are no satisfactory alternatives (under FDA accelerated to 1mg/ then 1000mg every 6 weeks, the combination of nivolumab/ipilimumab has been approved by the FDA and EMA for patients with metastatic colon cancer with MSI HMMR, that have progressed",
      "start_page": 222,
      "end_page": 239
    },
    {
      "heading": "C61",
      "text": "1,600,000 cases and 366,000 deaths per year. Precautionary control with the PMS assaying of the PMS as the baseline treatment for the PMS as the baseline treatment for the PMS, the PMS as the baseline treatment for the PMS, the PMS as the baseline treatment for the prostate cancer in the localized stage often leads to the identification of patients with an increase in PSA alone (biochemical recurrence in general). Such relapses generally (PET-PSMA). recurrence is that of the American Urological Society (A)\n\nPatients were also required to have PSA values  1 ng/ml since they had or PSA values aggravation of at least 2 ng/ml above nadir since they had previously undergone only a inhibition if PSA ( 0.2 ng/ml) could not be detected after 36 weeks of treatment. Treatment should be started again when PSA has increased to  2.0 ng/ml for patients who had previously undergone radical prostatectomy",
      "start_page": 241,
      "end_page": 243
    },
    {
      "heading": "(i)",
      "text": "Abiraterone acetate, 1000mg/day pre-food combined with prednisone 5mg once a patient who has at least 2 of the 3 following characteristics: Gleason score 8, presence",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "(ii)",
      "text": "Apalutamide 240mg/day for both patients with high and low disease load",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "(iii)",
      "text": "Enzalutamide 160mg/day for both patients with high and low disease load",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "(i)",
      "text": "Chemotherapy with dositaxel (75 mg/m2 every 3 weeks) for 6 cycles with concurrent administration of abiraterone acetate 1000mg daily pre-food and prednisone 5mg twice daily to disease progression. Treatment is based on the results of the PEACE-1 study, whose analysis (ADT+Dositaxel+Abiraterone) in patients with high disease load.",
      "start_page": 244,
      "end_page": 244
    },
    {
      "heading": "(ii)",
      "text": "150 mg/day with dositaxel (75 mg/m2 dosed with a dosed dosed dosed dosed at a dosed dosed dosed dosed dosed dosed dosed dosed at a dosed dosed dosed dosed dosed dosed dosed at a dosed dosed dosed dosed dosed dosed dosed at a dosed dose of 600 mg/m2 daily dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed daily dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed dosed\n\nAbiraterone acetate, 1000mg/day pre-eating, prednisone doses of 5mg per day dosed twice daily dosed with Olaparib 300 mg twice daily in patients in whom chemotherapy is not clinically indicated. The indication of the combination is regardless of presence of HRR genetic mutations and 4. Enzalutamide 160 mg/day, with or without food combined with Talazoparib 0.5 mg/day\n\nPrior to initiation of treatment, the positive state BRCA should be documented with use. The radiotherapy-relaxial hemoglobin-responsive hemoglobin-responsive hemoglobin-responsive hemoglobin-responsive hemoglobin-responsive hemoglobin-responsive therapy (Prostate Specific Membrane Antigen) may be associated with the use of radiopharmaceutical 177Lu-vivotide tetraxetan, has demonstrated survival benefit in pre-treated patients with post-re-re-re-receptive therapy.\n\nNote 3: Suspicion of small-cell prostate cancer is set in patients with a high pleural pleural pleurisy pleurisy pleurisy + pleurisy pleurisy pleurisy pleurisy + pleurisy pleurisy pleurisy pleurisy + pleurisy pleurisy pleurisy + pleurisy pleurisy + pleurisy pleurisy pleurisy , pleurisy pleurisy pleurisy pleurisy pleurisy pleurisy pleurisy pleurisy pleurisy pleurisy .\n\n",
      "start_page": 244,
      "end_page": 258
    },
    {
      "heading": "Megatherapy (HDCT)",
      "text": "Over 3 days over 3 days of Mobilizing: VeIP x 1 HD, (Coboplatin 2100mg/m & Etoposide 2250mg/m ) x 2 INDINA UNIVERSITY ac over 3 days of Mobilizing: TI x 2 HD: ( Carboplatin AUC=24 & Etoposide 1200mg/m )",
      "start_page": 258,
      "end_page": 260
    },
    {
      "heading": "C64",
      "text": "Genetic syndromes (Von Hippel-Lindau's disease) Cortisal-resonant-resonant-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-responsive-resonsive-resonsive-resonsive-resonsive-resonance-resonance-resonsive-resonsive-resonance-resoning-resoning-resoning-resoning-resoning patients-resoning patients-resonance-resoning patients-resoning patients-resonative-resonative-resoning patients-resonative-resonative-resonative-resonative-resonative-resonative-resonance-resoning patients-resonative-resonative-resonance-resonance-resonance-resonance-resonance-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonsive-resonative-resonative-resonance-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonance-resonative-resonant-resonative-resonative-resonative-resonative-resonative-resonant-resonative-resonant-resonant-resonant-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonative-resonant-resonative-resonative-resonant-resonant-resonative-receptant-resonant patients-receptant-receptive-reson\n\nAnd while SURTIME did not have statistical validity in the results, CARMENA was shown to be the most dosed patients in the placebo-associated clinical trial as well as to be the most dosed patients in the placebo-associated clinical trial assay (Pubanumab+Cuban+Cuban+Cuban+Cuban+Cuban+Cuban+Cuban +Cuban+Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cuban=Cub\n\nagain taken I/O + TKI, that there are no studies to indicate the next treatment-responsive option. There are Axibinib (class 1) Cabozantinib + Everolimus (class 1) Everolimus Sorafenib Sunitinib Pazopilimus (class 2B)\n\nThere appears to be efficacy, mainly at ORR level.In addition, patients treated with the regimen of bilirubin should be treated with bilirubin + bilirubin + bilirubin + bilirubin + bilirubin + bilirubin + bilirubin + bilirubin + bilirubin + bilirubin + bilirubin + bilirubin + in patients with advanced carcinoma (4D) : The FDA has recently approved administration of the oral inhibitor of bilirubin + bilirubin + bilirubin + bilirubin + bilirubin + bilirubin + bilirubin bilirubin bilirubin biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary therapy biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary biliary",
      "start_page": 263,
      "end_page": 269
    },
    {
      "heading": "B3. DOSOLOGY – HOW SYSTEMICAL TREATMENT WORKS",
      "text": "1. Sunitinib 50 mg/day, po, for 4 weeks followed by 2 weeks discontinuation 2. Pazopanib 800 mg, daily, continuously, PO 3. Sorafenib 400 mg, 2 times daily, continuously, PO 4. Bevacizumab 10 mg/kg, IV, every 2 weeks + Interferon-a 9 MU, YD, three weekly 5. Temsirolimus 25 mg, IV, weekly",
      "start_page": 270,
      "end_page": 270
    },
    {
      "heading": "6. Everolimus 10 mg/day, PO",
      "text": "7. Lenvatinib 18 mg + Everolimus 5 mg daily, per os. 8. Aximbib 5 mg, 2 times daily PO (substituted upward of dose on 9. E rlotinib 150 mg/day, PO 10. Nivolumab 240mg every 2 weeks over 30 minutes or 480mg every 4 weeks 11. Nivolumab 3mg/kg + Ipilim",
      "start_page": 270,
      "end_page": 270
    },
    {
      "heading": "14. Cabozantinib 60mg/day - PO",
      "text": "15. Pembroizumab + Axitinib, 200 mg every 3 weeks, IV and Axitiinb 5 mg from 16. Pembroizumab 200 mg every 3 weeks, or 400 mg every 6 weeks, IV and Lenvatin Belzutifan 120 mg once daily regardless of food (3x 40mg tablets) mab, continues nib 20 mg once Note 1: In Europe, there is no approval for the combination of avelumab + axib",
      "start_page": 270,
      "end_page": 271
    },
    {
      "heading": "B 4. ESSENTIAL OBJECTION",
      "text": "In patients with bone metastases and creatinine clearance of > 30 μL min, the administration of hepatic hemoglobin at a dose of Cimbituric Cimbituric Cimbituric T-Cimbitin-associated T-Cimbitin-associated Cimbitin-associated Cimbitin-associated Cimbitin-associated Cimbitin-associated Cimbitin-treated patients was recommended.",
      "start_page": 271,
      "end_page": 279
    },
    {
      "heading": "2. Complete, \"aggressive\" TURBT",
      "text": "3. Cisplatin 20mg/m2 (days 1-5 .22-26 IV) concurrently with radiotherapy. Alternately Cisplatin 40mg/m2/week concurrently with radiotherapy. Retest with cystoscopy after 2-3 4. Cisplatin 100 mg/m2 (days 1.22 IV) concurrently with radiotherapy 1.8 Gy/day, up to a total dose of 40 Gy. Cys",
      "start_page": 279,
      "end_page": 279
    },
    {
      "heading": "Cisplatin + Gemcitabine",
      "text": "Cisplatin 70 mg/m2 (day 1) IV + Gemcitabine 1000 mg/m2 (day 1, 8), IV Dosek-daenes 2e1 M hVmAerCe for 4 cycles Methotrexate 30 mg/m2 (day 1) IV + Vinblastine 3 mg/m2 (day 1) IV + Doxorubicin 30 mg/m2\n\nWhen compared with DDMVAC preoperatively, it appears to have lower rates of pCR, DFS, but better profile Based on the study GETUG-AFU V05 VESPER administration of chemotherapy with 6 cycles of ddMVAC is superior against 4 cycles of Gemcitabine/Cisplatin, in terms of interval free recurrence of Cisplatin disease at a reduced daily dose (either days 1 & 2 or 2",
      "start_page": 280,
      "end_page": 282
    },
    {
      "heading": "1. Cisplatin + Gemcitabine",
      "text": "Cisplatin 70 mg/m2 (day 1) IV + Gemcitabine 1000 mg/m2 (days 1, 8), IV",
      "start_page": 282,
      "end_page": 282
    },
    {
      "heading": "2. Carboplatin + Gemcitabine",
      "text": "Carboplatin AUC 4.5-5 (day 1) IV + Gemcitabine 1000 mg/m2 (days 1, 8), IV 3. Dose-dense MVAC a. Methotrexate 30 mg/m2 (day 1) IV + Vinblastine 3 mg/m2 (day 1) IV + Doxorubicin 30 mg/m2 (day 1) IV + Cisplatin 70 mg/m2 G1",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "4. MVAC",
      "text": "a. Methotrexate 30 mg/m2 (days 1, 15, 22), IV + Vinblastine 3 mg/m2 (days 1, 15, 22), IV + Doxorubicin 30 mg/m2 (day 2), IV + Cisplatin 70 mg/m2 (day 2), IV b. Every 28 days",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "5. Cisplatin",
      "text": "70 mg/m2 (day 2) IV + Gemcitabine 1000 mg/m2 (days 1, 8, 15), IV",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "6. Enfortumab Vedotin/Pembrolizumab*",
      "text": "Enfortumab vedotin 1.25mg/Kg (days 1.8 up to disease progression) + pembrolizumab 200mg day 1 up to",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "7. Nivolumab/Gemcitabine/ Cisplatin *",
      "text": "Nivolumab 360 mg (day 1 ) + Gemcitabine 1000 mg/m2 (days 1.8 ) + Cisplatin 70 mg/m2 (day 1) every 21 days for 6 cycles and then Nivolumab 480 mg every 28 days up to 2 years The above treatment regimens have FDA approval, but not EMA (3/2024). II. ANOTHERAPE 1st line in patients unsuitable for cplatis.",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "Pembroizumab 200mg every 21 days, day 1, IV or 400 mg IV day 1, every 42 days with",
      "text": "CPS 10III. Maintenance INSURANCE after 1st line chemotherapy",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "Avelumab 800mg IV every 14 days",
      "text": "Galsky et al. :ECOG PS 2, Creatinine clearance 60ml/min, significant peripheral neuropathy or hearing disorder, heart failure NYHA III. Patients who are eligible for cisplatin and have a high PDL1 expression should receive cisplatin-based chemotherapy rather than immunotherapy.",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "The administration of 1st-line immunotherapy, either with Atezolizumab or Pembrolizumab in patients with",
      "text": "high PDL1 expression should be preferred in patients who do not accept any chemotherapy. unfit for cisplatin administration. In addition, there is a restriction of EMA approval only in patients with positive PDL1 expression. Atezolizumab requires PD-L1 expression  5% in tumor-filtration immune cells (IC). PD-L1 expression was evaluated with VENTANA PD2)",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "Maintenance treatment with Avelumab after first-line chemotherapy demonstrated significant",
      "text": "survival advantage over optimal supportive treatment and is now considered the standard of care.",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "Avelumab maintenance is the preferred option even for patients with high expression",
      "text": "PDL1 that are unsuitable for cisplatin and received carboplatin-based chemotherapy.",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "Atezolizumab",
      "text": "Nivolumab",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "Atezolizumab 1200mg every 21 days IV",
      "text": "Pembroizumab Nivolizumab 240mg every 14 days IV or 480mg IV every 28 days Pembroizumab 200mg clinical benefit was shown in 21 days, day 1, IV or 400 mg IV day 1, every 42 days All of the above immunotherapeutic drugs have been approved by the FDA and EMA for No PDL1 expression control is required for administration of immunotherapy with the above drugs for The initial approval of Atezolozumab was based on the results",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "IV. Chemotherapy after platinum-based chemotherapy failure",
      "text": "Vinflunine 280-320 mg/m2 IV every 21 days Vinflunine has shown activity as a 2nd-line treatment in metastatic urothelial cancer and is administered at the dose of 280-320 mg/m2 IV every 21 days. After special justification other drugs such as Paclitaxel and Docetaxel may be administered.",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "1. Enfortumab Vedotin",
      "text": "Enfortumab Vedotin 1.25mg/Kg IV(days 1, 8, 15) every 28 days",
      "start_page": 286,
      "end_page": 286
    },
    {
      "heading": "2. Erdafitinib",
      "text": "tb Erdafitinib 8mg/day",
      "start_page": 286,
      "end_page": 286
    },
    {
      "heading": "3. Sacituzumab Govitecan",
      "text": "Salituzumab Govitecan 10mg/Kg (days 1.8), treated with a combination-responsive modulative modulator (ADF), a combination of an antibody-drug (ADC) against the adhesion molecule Nectin-4 and a microtubule inhibitor was approved based on the results of the phase III clinical study EV-301 that showed a benefit of overall survival against chemotherapy and immunotherapy with an inhibitor PD1",
      "start_page": 286,
      "end_page": 287
    },
    {
      "heading": "C43, C43.0, C43.1, C43.2, C43.3, C43.4, C43.5, C43.6, C43.7, C43.8, C43.9",
      "text": "E1n. and Ipixilism. Lately administered as an adjunctive dose of E.F.A.F.I.I.I.I.I.L.A.C. at a full-term dose of E.F.A.L.A.C. in at least 2 weeks of E.F.A.C.C. at stage IIb, IIc or III (according to A.J.C.C.C.) It is approved at 10mg doses every 3 weeks after booster doses every 3 months to 32 months to 32.",
      "start_page": 290,
      "end_page": 290
    },
    {
      "heading": "4. Dabrafenib+trametinib",
      "text": "The FDA approved on 5/18 the administration of the combination to BRAF+ fully excluded stage III melanoma and with at least filtration of >1 mm into lymph node-guard at 150mgx2 +2mg/day respectively and for disease and lymph node cleansing, within 12 weeks ] [there is approval and EMA] 1st line BRAF wild-type",
      "start_page": 291,
      "end_page": 291
    },
    {
      "heading": "1. Ipilimumab",
      "text": "2. Nivolumab 3mg/kgiv every 3 weeks (4 cycles) 240mg per 2 weeks or 480mg per 4 weeks or 3mg/kg per 2 weeks or 6mg/kg per 4 weeks 3. Roeems μbr oalpizoudmektb 2 t0xmikgo tequitha 3rd with dpoemra 4.",
      "start_page": 291,
      "end_page": 291
    },
    {
      "heading": "1. Ipilimumab 3mg/kgivevery 3 weeks (4 cycles)",
      "text": "2. On choresis of the combination at 1 line, the phase II (LEAP-004) study of biliary fibrillation at a total dose of 200 mg/d at the same time as the lenvantinib + 2nd line of BRAF positive disease may be administered immunotherapy according to BRAFwild-type standards at 1st or 2nd line or at the same time\n\nAfter the first 28 days, the recommended dose of atezolizumab is 840 mg as IV injection in 60 minutes each cobimetinib 60 mgorally independent of pneumonic treatment (21 days on and 7 days rest) and vemurafenib 720 mgorally If the first infusion of atezolizumab is well tolerated, all subsequent treatments are administered in 30 minutes. Imlygic (T-VEC) of adult patients with non-except.",
      "start_page": 291,
      "end_page": 292
    },
    {
      "heading": "DTIC",
      "text": "a. 250 mg/m2/day iv for 5 days or b. 1000 mg/m2/day 1 every 21 days c. 800mg/m2 every 15 days Temozolomide 200 mg/m2/day po for 5 days every 28 days Interleukin-2 (high doses) 720,000 IU/Kg, iv every 8 hours, times 14 shots. Recurred in mid-Protocolles",
      "start_page": 293,
      "end_page": 293
    },
    {
      "heading": ": Cisplatin 80 mg/m2, vinblastine 8 mg/m2, DTIC 800mg/m2 iv every 21 days.",
      "text": "Vindesine 2.5 mg/m2 day 1, IV",
      "start_page": 293,
      "end_page": 293
    },
    {
      "heading": "DTIC 300 mg/m2 days 1-3, IV every 21 days",
      "text": "Paclitaxel 175mg/ m2+CarboplatinAUC 5-6 IV Note 1: For the administration of TKIs, the control of the tumor as a treatment for the existence of a mutation of V600E and others found at a lower frequency may be required, as it is a dr. lomide (with Cisplatin, B-RAF axes, especially the primary follicular site should be controlled for c-kit mutations and in their existence.",
      "start_page": 293,
      "end_page": 294
    },
    {
      "heading": "3. Paclitaxel",
      "text": "4. TPeemgyolzaotelodmInidtee rferon α-2b FA6.ManeKoAa dEjNuvTaOnSt aNoDsEioXIXIH     .",
      "start_page": 294,
      "end_page": 294
    },
    {
      "heading": "1. Nivolumab+relatlimab",
      "text": "2. T-VEC 31. R. Dummer, A. Hauschild, M. Guggenheim. . Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. AnnOncol (2010) 21 (suppl 5): v194-v197.",
      "start_page": 294,
      "end_page": 297
    },
    {
      "heading": "A. PLACIDES SKIN CANCER",
      "text": "The total squamous carcinoma of the skin (cutaneousquamouscellcarcinoma, CSCC) is treated with a highly-advanced cscresponsive modulus (dissociative cscresive modulation) that is not treated at the most. The most common cscresponsive modulus is csaclystic modulation (cresponsive modulation) with the csponsive modulsive modulusm.\n\nThe median duration of follow-up was 16.5 months for the mCSCC group of patients who received 3 mg/kg every 2 weeks (Q2W), 9.3 months for the laCSCC group of patients who received 3 mg/kg Q2W and 8.1 months for the mCSCC group of patients who received 350 mg Q3W. The confirmed objective response rate (ORR) was 49.2%, 43.6% and 41.1% for the objective response rate (ORR)",
      "start_page": 302,
      "end_page": 303
    },
    {
      "heading": "A. TREATMENT OF PROGRESSED (TOWNLY PROGRESSED AND metastatic) DISEASE",
      "text": "Indications: Stages II with > 2 risk factors, III and IV (according to AJCC-UICC) 1. Cemiplimab + quintab is not required with flexibrexel flexibrex. 2. In contraindication therapy with checkpoint inhibitor or as a second line of systemic therapy after failure of cemiplimab out of indication: Carboplatin + paclitaxel ux\n\nPrimary Analysis of Phase 2 results of Bemiplimoma's disease at the most advanced rate of disease at the most advanced rate of Bemiplimab, a human monoclonal carcinoma-1, in patients with locally advanced squamous cell carcinoma 2019 American Society of Clinical Oncology Annual Meeting. Chicago, Illinois, 2019.\n\nThe efficacy and safety of cemiplimab in patients with laBCC or mBCC, who had experienced a baseline progression of the disease with HHI, had intolerance to prior treatment with HHI, or had no improvement better than SD after 9 months of treatment with HHI was assessed in study 1620, an open-label, multicentre, non-randomized study [11]. A total of 119 patients with advanced BCC were included in the analysis.",
      "start_page": 303,
      "end_page": 308
    },
    {
      "heading": "A. TREATMENT OF PROGRESSED (TOWNLY PROGRESSED AND metastatic) DISEASE",
      "text": "VismodegibPO 150mg daily for patients with symptomatic metastatic basal cell carcinoma SonidegibPO 200mg daily for patients with locally advanced basal cell carcinoma (BCC) Cemiplimab 350mg iv every 3 weeks for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) in adult patients who have developed dysphoresis of the disease.",
      "start_page": 308,
      "end_page": 308
    },
    {
      "heading": "11. Summary of Product Characteristics (cemiplimab).",
      "text": "Pekkel carcinoma [MCC] is a rare virulent neuroendocrine-mediated cytobulosis of the skin. [1] Peklipin-adjuvant-adjuvant abvulsant absorbsorbs [DCC]-adjuvant absorbs absorbsorbsorbs absorbsorbs absorbsorbs.\n\nThe regimen Alternatively, in patients not suitable for ifosfamide (as in patients with leiomyoscarcoma where the drug ifosfamide is less effective): Doxorubicin 70 mg/m2 IV (day 1) and Dacarbazine 400 mg/m IV (days 1-3) Trabectedin 1.5 mg/m2 IV, on 24-hour administration by a central catheter, 21 days",
      "start_page": 310,
      "end_page": 316
    },
    {
      "heading": "1. Doxorubicin",
      "text": "Ifosfamide 25 mg/m2 IV (days 1-3) or Epirubicin 75 mg/m2 IV (day 1) alone or with and with 3gr/m2/H IV (days 1-3), along with Mesna at a dose of 60%- 100% of ifosfamide 2. Tyrsabtetentetadi nsupport with G-CSF regimen.",
      "start_page": 316,
      "end_page": 316
    },
    {
      "heading": "3. Doxorubicin",
      "text": "Dacrbazine 70 mg/m2 IV (day 1) and 400 mg/m IV (day-to-day liposomal sarcoma patients treated with a day-to-day regimen of decompressed decompression (day-to-day decompression patients treated with decompression IV.) Impaired day-to-day decompression patients (day-to-day decompression patients treated with IV-CSF.",
      "start_page": 316,
      "end_page": 317
    },
    {
      "heading": "1. Gemcitabine 900 mg/m2 IV (days 1, 8) with or without",
      "text": "Docetaxel 80-100 mg/m2 IV (day 8) Recommended for use with C-CSF at day 9-15 in combination. 2. Cyclophosphamide 500 mg/m2 IV (day 1) and Vincristine 1.5 mg/m2 IV (maximum dose 2 mg), (days 1 and 5) and Doxorubicin 50 mg/m2 IV (day 1)\n\nIt is recommended, Solitary Fibrous Tumor/Hemangiomilimodilimodilimodilimodilimodilimodilimodyloximate (reports for activity of sunitinib and the combination of temozolomide/bevacizumab), Angiosarcomine (sorafenib, bevacizumab, PD1 inhibitor in dermal Pigmented Vilonodular Synovitic\n\nless than 2 metastases daily CPR is shown to be metopreceptive in patients with CPR.Crucative mutation of cib.Crucosis of cib.Crucosis of cib.Crucosis of cib.Crulture of cib.Crulture of cib.Crulture of cib.Crulture of cib.Cruc.Cruc.Cr.Cr.Cr.Cr.Cr.Cr.Cr.Cr.R.Cr.Cr.Cr.Cr.Cr.\n\nNote 2: Administration of imatinib at a dose of 800 mg in the first place is recommended for patients with a mutation in exonium 9 of the KIT gene. 2. Avapritinib 400 mg daily, PO, for patients with PDGFRA (D842V) mutation until disease progression or non 3. Sunitinib 50 mg daily PO, in 6-week cycles (drug administration for 4 weeks followed by a 2-week break), until relapse. Also, continuous administration of s",
      "start_page": 317,
      "end_page": 322
    },
    {
      "heading": "Regorafenib,160mg 3 weeks on/ one week off, imatinib sunitinib.",
      "text": "4. Ripretinob after failure at and 5. Cabozantin complex, 1ib50 mg treated with imatinib, and regorafenib. 6. , 60 mg daily as 4 line of treatment (out of the indication) DrugCaAv NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN\n\nIV line therapy recommended the drug pecylateddliposomaldoxibicin (20 mg/m every 23 weeks IV, and alternatively paclitaxel (100 mg/m every 3 weeks or 60 mg/m every week IV), as the subsequent line of treatment recommended the pomalidomide (4 or 5 mg daily oral). Also can be given: borezomib (1.6 mg/m IV).\n\nIV: 3 mg/m2 IV: 3 mg/m2 IV: 3 mg/m2 IV: 2 mg/m2 IV: 2 mg/m2 IV: 2 mg/m2 IV: 3 mg/m2 mg/m2 IV: 3 mg/m2 mg/m2 IV: 3 mg/m2 mg/m2 IV: 4 mg/m2 mg/m2 mg/m2 mg/m2 dose: 3 mg/m2 mg/m2 mg/m2 mg/m2 mg/m2 mg/m2/m2/m2/m2/m2/m3 IV/m3 IV/m2 IV/m3 IV/m2/m2/m2/m3 IV/m2 d/m3 IV/m2 IV/m3 IV/m2 d/m2 IV/m2 d/m2 d/m2 d/m2 d/m2 d/m2 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d/m3 d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d d\n\nCifamurtide in chemotherapy with doxorubicin.40 mg, cisplatinate + phosphamide plus plus co-administration of 1ifamurtide in chemotherapy with doxorubicin, cisplatin with or without Note 3: The addition of the immunomodulating agent mifamide to the postoperative combination Ifosfamide /Etoposide with or without Carboplatin",
      "start_page": 322,
      "end_page": 342
    },
    {
      "heading": "VDCA/IE",
      "text": "Vinceristine 2 mg/m2 (up to maximum 2 mg), day 1, IV Doxorubicin 75 mg/m2, day 1, IV Cyclophosphamide (+mesna) 1200 mg/m2, day 1, IV Actinomycin-D 1.25 mg/m2, day 1 (up to maximum 2.5 mg) Ifosfamide (+mesna) 1800 mg/m2, days 1-5, IVtopside",
      "start_page": 342,
      "end_page": 342
    },
    {
      "heading": "B. STATISTICAL DISEASE",
      "text": "In relapsed or metastatic sarcoma Ewing treated with first line of chemotherapy, 1 μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ μd/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/ d/",
      "start_page": 343,
      "end_page": 348
    },
    {
      "heading": "Grade Volumes 1",
      "text": "Id grade I tumors are circumscribed, non-diplococtic fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal fractal ci\n\nIn addition between both the IDH wild type and the IDH mutatogenous metabolomic gliomas are now classified by the -go's as glycade 4: EGFR amplification, and the cytogenetic signature +7/-10: If found in IDH wild type glioma, the tumor is now classified as a glioplasm IDH wild type.",
      "start_page": 349,
      "end_page": 350
    },
    {
      "heading": "- PCV:",
      "text": "CCNU (lomustine) 90 (cycle 1) - 110 (from cycle) is administered clinically as a follow-up dose of chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoide chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside chromoside",
      "start_page": 351,
      "end_page": 352
    },
    {
      "heading": "ASTROCYTOMA IDH – mutant grade 3 (previously called anaplastic astrocytoma)",
      "text": "at least the taking of a biopsy. Then CMR is recommended. Use at the same time as CMR Temozolomide claudication is mainly recommended in clinical treatment (75 mg/m2/day PO for 6-7 weeks continuously with CMR 2Gy/day for 5 days/week for 6-7 weeks as 60 Gy) was studied in the CATHON study and does not add benefit(24). After the end of CMR syndrome",
      "start_page": 352,
      "end_page": 352
    },
    {
      "heading": "ASTROCYTOMA IDH – mutant WHO grade 4",
      "text": "This entity with the oldest classification was described as IDH-mutant glioblastoma. It also now includes IDH – mutant astrocytomas with CDKN2A/b elimination. Patients with this tumor can be managed either as an IDH-mutant WHO grade 3 or as an IDH wild type glioblastoma below (bleed 4.5).",
      "start_page": 352,
      "end_page": 352
    },
    {
      "heading": "LANGUAGE IDH – wild type WHO grade 4",
      "text": "The term relates to the previously known as primary (IDH wild dose) gluotide-combined efficacy of gluotide-treated patients and also to the Psiclotide-combined efficacy of Psiclotide-combined efficacy (Psiclotide-combined efficacy) of Psiclotide-combined efficacy (Psiclotide-combined efficacy) patients with Psiclomid-combined efficacy (supramaxal safe replication).\n\nIf treatment is recommended, administration of a dose-substituted CMR or temozolomide-substituted dose (in MGMT) is recommended at a dose-substituted daily dose (in μgMT) of μg/ μg/ μg/ μg/ μg/ μg/ μg/ μm/ μg/ day. The imaging frequency in MGMT methyl tumors is also indicated after administration of μm/ μm/ μm/ μm/ μm/ μm/ μm/ μm/ μm/ μm/ μm/ μm/ μm/ μm/ μm/ μm/ μm/ μm/ μm.\n\ndrugs such as BRAF mutations (dabrafenib/tramectinib, vemurafenib/cobimetinib) (6) (8) and NTRK (larotrectininb, entrectinib) (53) (54) Myeloblastoma is now categorized by molecular criteria in 4 group: Group 1 WNT – activated (wnt signaling) Group 2",
      "start_page": 352,
      "end_page": 355
    },
    {
      "heading": "3. Lomustine 75 mg/m d1",
      "text": "Each 6 weeks as maximum 8 cycles 1. Vincristine biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics and biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics and biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics biologics\n\nNevertheless, the differentiation of staging of oropharynx cancers based on whether or not they are associated with HPV is mainly of predictive significance and radiotherapy in patients with a prospect of larynx retention (organ preservation strategies). The (stages III, IV) is also indicated in metastatic or locally advanced relapsing disease that is not locally treatable. Immunotherapy (pembrolizumab)",
      "start_page": 355,
      "end_page": 364
    },
    {
      "heading": "1. PF+ pembrolizumab:",
      "text": "(in patients with PDL1 CPS expression1) Pembroizumab 200 mg and Cisplatin 100 mg/m2 or Carboplatin AUC 5, day 1, IV and 5-FU 1000 mg/m2, days 1-5 in IV continuous infusion (6 cycles followed by maintenance with pembroizumab until unacceptable toxicity or a maximum of 24 months).",
      "start_page": 364,
      "end_page": 364
    },
    {
      "heading": "2. Pembroizumab:",
      "text": "(in patients with PDL1 CPS expression1) Pembroizumab 200 mg every 21 days (up to unacceptable toxicity or a maximum of 24 months).",
      "start_page": 364,
      "end_page": 364
    },
    {
      "heading": "3. PF + Cetuximab [EXTREME figure]:",
      "text": "(in patients with PDL1 expression CPS1) Cisplatin 100 mg/m or Carboplatin AUC 5 day 1, IV and 5-FU 1000 mg/m , days 1-4 in IV continuous Cetuximab infusion on days 1, 8, and 15 (IV 400 mg/m2, day 1 for cycle 1 and then 250 mg/m2 each (6 cycles and then maintenance with cetuximab until unacceptable toxicity or disease)",
      "start_page": 364,
      "end_page": 364
    },
    {
      "heading": "4. TPEX (alternatives of EXTREME scheme)",
      "text": "Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, day 1 and Cetuximab on days 1.8, and 15 (IV 400 mg/m2, day 1 for cycle 1 and following",
      "start_page": 364,
      "end_page": 365
    },
    {
      "heading": "5. TP",
      "text": "IVplatin 75 mg/m2, day 1, IV and Docetaxel 75 mg/m2, day 1, IV 6. CP Cisplatin 75-100 mg/m , IV and Paclitaxel 175 mg/m , IV Carboplatin AUC5, IV, day 1 and 5-FU 1000 mg/m , days 1-5 in IV continuous infusion Cetuximab 400 mg/m IV (charge), then",
      "start_page": 365,
      "end_page": 365
    },
    {
      "heading": "1. Nivolumab 240 mg regardless of PD-L1 expression",
      "text": "have not taken immunotherapy on the 1 line or those who have taken EXTREME on the 1 line) 2. Pembroizumab 200 mg in patients with PD-L1 TPS expression50%",
      "start_page": 366,
      "end_page": 366
    },
    {
      "heading": "4. Docetaxel 75 mg/m2, IV",
      "text": "IV. Methotrexate 40 mg/m weekly, IV (3 doses equal to one day of radiotherapy at 1, Docetaxel 75 mg/m , IV every 21 days and Cetuximab 400 mg/m IV (charge), and then 1 Cetuximab 250 mg/m , per week every 21 days or Cetuximab 500 mg/m every 14 days\n\nPF and Cisplatin/Paclitaxel combinations have shown equivalence, but Paclitaxel is not given In metastatic disease, in regimens used with Cetuximab alone, the latter continues 4: In patients with PDL1 CPS expression 1 can be administered as a first-line treatment or a combination of pembrorizumab with chemotherapy or chemotherapy with pembrorizumab.",
      "start_page": 366,
      "end_page": 367
    },
    {
      "heading": "patients with PDL1 TPS expression 50%. nivolumab is administered independently of PDL1.",
      "text": "MTX is usually administered as a rescue therapy or in patients with low PS or in patients with Cibidium fibrosymbinase (Cibplatinase-Cibulinase-Cibulinase-Cibulinase-Cibulinase-Cibulinase-Cibulinase-Cibulinase-Cibulinase-Cibulinase-Cibulinase-Cibulinase-Cibulinase-Cy.\n\nIpifarnib has received Breakthrough Therapy Designation from the FDA's habiliary hemorrhagic tumor haematopoietic tumor haematopoietic tumor haematopoietic haematopoietic haematopoietic tumor haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematopoietic haematography\n\nIn patients with T1 tumours (> 1 cm) or T2 N0 M0 M0 or multifocal developmental T1 M0 M0 dosed at a maximum daily dose of 0.04 μM2 dosed at a dose of 0.04 μM2 dosed at a dose of 0.24 μM2 dosed at a dose of 0.02 μM2 dosed at an appropriate dose of 0.04 μm2 dose. Patients not more specifically treated with the administration of I (if.) with either I (if.\n\nPatients who carry mutations in the BRAF, RET, NTRID genes may receive treatment with a dose-responsive combination of riboflavin-responsive therapy [In patients with ribofatin-responsive ribofin-responsive therapy with ribofatin-responsive treatment with riboflavin-responsive therapy with ribofin-responsive therapy in patients with ribof NRT1\n\nInhibitors of BRAF do not have FDA or EMA approval, however, in phase II patients who have been tested have shown encouraging effects on the median PFS in patients with papillary thyroid carcinoma and BRAF mutation V600E [49-51]. Other micromolecular kinase inhibitors have been tested, such as Sunitinib, Pazopanib, Axinitib, Molinosib, Desipitastat.",
      "start_page": 367,
      "end_page": 379
    },
    {
      "heading": "V. MYELOEIDIS CARKINOS THIREODIES",
      "text": "is a manifestation of inherited syndromes, such as MEN 2A, MEN 2B and familial myeloid haematoconvulsant haematoconvulsant haematoconvulsant haematoconvulsant haematoconvulsant haematoconvulsant haematoconvulsant haematoconvulsant haematoconvulsant haematoconvulsant haematocon haema\n\nIn the NIBRETTO 531, a randomised phase 3 study, the selpercatinib-responsive dose of interferon-responsive therapy is comparable to the placebo-responsive dose and the vandetanib dose at the first line of myeloid thyroid carcinoma (MTC) with a RET mutation, in patients with a pre-planned interim analysis with 12 months median follow-up, the median PFS value was not reached for selpercatinib while it was 16.8 months.\n\nThe treatment in anaplastic thyroid cancer is determined by the stage and effects of the BRAF mutation V600E, the induction treatment with dabrafenoch (150 mg twice daily) and trametinib (2 mg daily) is recommended to treat the tumor completely. doxorubicin 10 mg/m weekly, IV, in combination with radiotherapy has also been tested [85].",
      "start_page": 380,
      "end_page": 384
    },
    {
      "heading": "III) DIAGNOSTIC APPROACH",
      "text": "imaging screening of the thorax and upper and lower ventricles (CTs or MRIs). Depending on the individual clinical trial the screening with PET/CT although described in retrospective studies is related to finding PET/CT Therefore the key role of PET/CT concerns specific clinical ‘scenarios' and mainly the investigation",
      "start_page": 390,
      "end_page": 390
    },
    {
      "heading": "IV) CONFERENCE",
      "text": "2. Women with metastasis in axillary LNs based on the guidelines for breast cancer st.In the event of a potential follicular lesion diagnosis (in the case of presence of 3. Men with vegetative or sclerotic ectonic metastases and increased PSA in the blood or positive for PSA pigmentation in the biopic material guidelines for the metastatic Ca prostate. The same is true for men with uncommon PSA in the blood or positive",
      "start_page": 391,
      "end_page": 394
    },
    {
      "heading": "2. Poorly differentiated neuroendocrine neoplasms (G3).",
      "text": "Screening of chest and upper and lower ventricles (CT/MRI) FDG-PET in the administration of chemotherapy with Cisplatin and Etoposide.",
      "start_page": 394,
      "end_page": 394
    },
    {
      "heading": "E. CHEMIOTHErapeutic schemata cape",
      "text": ".\n\n1) IVbomplatin AUC1, d1, IV + PaclitaQ 175mg/m , IV, d1 (Q21) x 8 cycles 2) Carboplatin AUC5, d1, IV + Docetaxel 75mg/m , IV, d1 (Q21) X 8 cycles 394 3) Cispla 4) Gemc 6) Oxalip 1200mg 7b)\n\n2A and below. Therapeutics (e.g. HER-2, F.M.G.R.C., NTR.S.A.) Functionality index syndrome syndrome syndrome (C.C.R.C.) or for the detection of biomarkers that can direct PD-L1 indicators, TMB, MSI) seems to be an emerging therapeutic approach for bone metastases patients can take bisphonate or Denosumab with 1. Greco FA, Hainsworth JD.\n\nOn the basis of this two-step approach (\"two-step\" sensitivity) sensitivity-complexity of dose-comparative therapy (C.C.C.R.R.R.R.R.C.R.C.C.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C.C\n\nPREVENTION SUPPLEMENT BEFORE THE FIRST CYCLE CHMEITHERAPE (PROTOGENY Preceded chemotherapy that caused hemorrhagic hemorrhage Grade>2 (1,000 neutrophils/mm ).\n\nPoor performance status (PS>2) Note 1: Hh porloerceptinocidoficinciducidocoducine (corticinocidinocid, ernind)x is absolute and in indications 2-5, G-CSF can be administered for regimens with NHL and age over 65, TAC regimen and combination TIP, Topotecan use in lung and ovarian cancer, CAV (ACO) regimen in the microcellular\n\nC. USE G-CSF FOR IMPLEMENTATION OF TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITIONAL TRADITION TRADITIONAL TRADITIONAL TRADITION TRADITION TRADITION TRADITION TRADITION TRADITIONAL TRADITION TRADITION TRADITION TRADITION TRADITION TRADITION TRADITION TRADITION TRAFFAL TRADITION TRAFFAL TRAFFAL TRAFFAL TRAFFAL TRAFFAL TRAFFAL TRAFFAL TRAFFAL TRAFFAL TRADIAL TRAFFAL TRAFFAL TRAFFAL TRAFFAL TRAFFAL TRAFFIC TRAFFIC TRAFFIC TRAFFAL TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFAL TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRAFFIC TRA\n\n95% chemokinotherapy [II, B] and Hb10g/dl level of blood glucose [punctual/asymptomatic/CIb8g/dl level]. Patients with severe Hb7-8g/dl anemia-related symptoms and the need for rapid correction of Hb8g/dl are required to achieve a level of Hb 1314 g/dl [I,A].\n\nJ Natl Cancer Inst 1999;91:16161634. 3. Mercadante cancer cancer in cancer, Marrazzo A, et al anemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000;26:303-311. 4. Wilson J, Yao GL, Raftery J, et al A systematic review and economiceva\n\nAlso effects of AIs on bone loss , in women with breast cancer without bone metastases, but none of these agents are recommended to reduce the incidence of fractures (I,A). Denosumab administered at a dose of 60 mg every 6 months significantly reduces the incidence of osteoporosis (I,A). An initial DEXA scan should be performed before starting treatment in men at an increased risk of fracture based on the FRAX algorithm.\n\n2.5Denosumab at a dose of 120 mg, administered subcutaneously every month, is superior to 1.Uccaldural failure factor 1,2xeumensic factor 2, and is not recommended as a therapeutic option for patients with bone metastases (I, B).Denosumab at a dose of 120 mg, administered subcutaneously every month, excels Zolendronic acid, approximately by 3.6 months (I, B).\n\nFor those who are already receiving a full therapeutic dose of LMWH, an alternative to a thrombocytic model of PMC should be recommended in patients who are at risk of COPD with COPD (1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 394,
      "end_page": 425
    },
    {
      "heading": "Patient characteristic Risk",
      "text": "Site of cancer Very high risk (stomach, pancreas) 2 High risk (lung, lymphoma, gynaecological, bladder, testicular, renal) 1 Pre-chemotherapy platet count 350,000 /microL 1 Haemoglobin concentration 10 g/dl or use of erythropoies",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "0 Low 0.8% 0.3%",
      "text": "1.2 Intermediate 1.8% 2%",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "3 or higher High 7.1% 6.7%",
      "text": "S t VTE > 1500 mg/m2 mg/m2 Epirubicin 90mg doxorubicin60m Actinomycin D Carboplatin AUC4 Methotrexate >50 mg/250 mg/m2 g/m2, mg/m2 /m2 – >200 m Nab-pa mg/m 2 g/m2 Na mg g/m2",
      "start_page": 425,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "125 mg at 150 mg IV",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "180 mg 300 mg/0.5 mg",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO?",
      "text": "2 mg 1 mg or 0.01 mg/kg IV; 1 transdermal patch; 10 mg",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "8 mg ; 8 mg IV",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "0.5 mg ; 0.25 mg IV",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "100 mg once",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "5 mg ; 5 mg IV",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO or",
      "text": "a. 20 mg IV b. 12 mg if 80 mg oral daily on days 2 and",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "(80 mg PO daily on",
      "text": "V mg per os or IV daily on",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "(30 to 90%)",
      "text": "(10 to 30%) Olanzapine 5 to 10 mg 5 to 10 mg on days 2 to 4.",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "Dexamethasone 12 mg or IV (8 mg per 8 mg per os or IV on days 2",
      "text": "os if we use up to 3.",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "Dexamethasone 12 mg or IV (8 mg per",
      "text": "os if we use",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "5-HT3 antagonist (one of the following):",
      "text": "μ (mu) of opiates with peripheral action.Naloxegenicity ratio.2004:Naloxegenicity ration synapse of opiates of constipation (opiaid-induced syndrome, OIC) in adult patients who have had inadequate and safety, which has been demonstrated in the Kodiac clinical program, [10-11] as well as in oncological patients through the pan-European study NACASY [12] and other studies [",
      "start_page": 432,
      "end_page": 433
    },
    {
      "heading": "1. Opioids.",
      "text": "The regulation of cancer pain, is made on the basis of the analgesic dose of WHO.The 5 principals of the dose are dosed at a dose of adipoxyreceptor.The maximum dose of adipoxyreceptor is dosed at a dose of 400 mg.The maximum dose of adipoxyreceptor should be dosed at a dose of 400 mg.The dose of adipoxyreceptor should be dosed at the same time.",
      "start_page": 435,
      "end_page": 438
    },
    {
      "heading": "Paroxysmal Cancer Pain (BTcP)",
      "text": "that is indicated for the treatment of paroxysmal carcinomatic pain (BTcP) in adult patients with (Abstral); they interact with the synaptic receptors; they are found in the synaptic receptors; they are found in the synaptic synaptic receptors; they interact with the synaptic receptors; they are found in the synapticis; they are found in the synaptic receptors; they are found in the synaptic receptors; they are found in the synaptic receptors; they are called synapticis; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are synaptic; they are, synaptic; they are, synaptic; they are, synaptic; they are synaptic; they are, synaptic; they are, synaptic; they are, syny.\n\n, Is the WHO analytical complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity complexity, complexity complexity complexity complexity complexity, complexity complexity complexity, complexity complexity, complexity complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity, complexity,",
      "start_page": 438,
      "end_page": 447
    },
    {
      "heading": "Grade 1 Mild:",
      "text": "Rash covering 10% BSA with or without symptoms (e.g. itching, feeling",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "Grade 2 Moderate:",
      "text": "Rash covering 10-30% BSA with or without symptoms (e.g. itching, feeling Rash covering >30% BSA without or with mild symptomatology",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "Grade 3 Serious:",
      "text": "Rash covering a daytime of >30% BSA with severe psychmatology. Limitation of Grade 4 symptonic reactions (symptonic reaction of symptonic reaction of symptonic reaction of symptonic reaction/symptonic reaction of symptonic reaction of symptonic reaction of sympton.\n\narpeothiorslcoosin biliary pharynx biliary pharynx biliary pharynx pharynx pharynx pharynx pharynx pharynx pharynx pharynx pharynx pharynx pharynx pharynx pharynx pharynx pharynx pharynx pharynx pharynx pharynx phynx phynx pharynx phynx phynx phynx phynx phynx phynx phynx phynx phynx phynx phynx phynx phynx phynx phynx phynx phynx phynxynxynx phynx phynx phynx phynxynx phynx phynxynx phynx phynxynx phynxyrx phynx phyrx phynxynxynx phyrhx phyrhxyrhx phyrhxynxyrhxynxyrhxyrhxynxynxynxyrhxyrxyrhxyrhxyrhxyrhxyrhxyrhxyrhxyrxyrxyrxyrxynxyrxyrxyrxyrxyrxyrxyrhxyrxyrxyrxyrhxyrxyrxyrxyrhxyrxyrhxyrxyrhxyrxyrhxyrxyrxyrxyrxyrhxyrxyrxyrhxyrxyrxyrhxyrxyrxyrxyrxyrxyrxyrxyrxyrxyrxyrxyrhxyrxyrxyrxyrxy\n\n- Tazarutone 0.05% of immunotherapy - UVB narthrombinosis, parsimonials of parsimonials - parsimonials of parsimonials - parsimonials of parsimonials - parsimonials of parsimonials - parsimonials of parsimonials - parsimonials of parsimonials - pars of pars - pars of pars.\n\nThe cooperation of pathologists oncologists with the other health professionals: the team injury injury disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder disorder\n\nWorld J Surgical Procedure Res. 2021; 4: 1335. 9. Otto S, et al (2021). Infection as an important factor in Medicine-Related Osteonecrosis of the Jaw (MRONJ). Medicina 57:463. 10. Nicolatou-Galitis O, Papadopoulos E, Vardas E, et al. (2020ve)\n\nThe approval applies to non-excluded or Pembrorizumab 200mg total dose, day 1, IV, every 21 days or Pembrorizumab 400mg total dose, day 1, IV, every 42 days 2. For patients, adults or children, those whose tumors are characterized as TRK fusion – positive, i.e. have either a NTRK fusion gene or a TRK fusion on both lines will be used (Trinoprotein)",
      "start_page": 449,
      "end_page": 467
    },
    {
      "heading": "Entrectinib 600mg, once a day, continuously",
      "text": "TMB (Tumor Mutational Burden, TMB limit 10 μb-symbolization patients/Mb) as determined by the NGS platform Foundation 1, CDx assay (or by other valid platforms) and have no other treatment options, the immunotherapeutic agent Pembrolizumab has been approved by the FDA. Pembrolizumab 200mg total dose, day 1, IV, every 21 days or Pembrolizumab",
      "start_page": 467,
      "end_page": 468
    },
    {
      "heading": "NTRK Gene Fusion",
      "text": "\n\nantiemetics e.g. levomepromazine or appropriate combinations Competitors 5HT3: ondasetron , granisetron, palonosetron Competitors NK1: aprepitant , fosaprepitant Corticosteroids: dexamethasone dopamine receptor antagonists: haloperidol, prokine Elassona sedatives: dexamethasone",
      "start_page": 468,
      "end_page": 480
    },
    {
      "heading": "Confrontation",
      "text": "Dexamethasone day 816 mg. Since there is no improvement after 5-7 days and undesirables of the day's A.C.R.R.R.A.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.A.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R\n\nRadbruch L, Elsner F, Trottenberg State Index Index Index Index Index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index index\n\n\n\nI'm repressing myelic symptomatic symptomatic symptomatic symptomatic symptomatic symptomatic symptomatic symptomatic symptomatic symptomatic symptomatic symptomatic symptomatic symptomatic symptomatic s symptomatic s symptomatic sym sym symptomatic sym symptomatic sym sym sym sym sym symsymptomatic symsysymsymsym sym sym sym sym sym sym sym sym symsym symsym sym sym sym symsymsym sym sym sym sym sym sym sym sym sym sym sym sym sym symsymsym sym symsymsymsymsymsym symsym symsym symsymsymsym symsymsym sym symsym symsymsym sym symsymsymsym sym symsym symsym symsymsymsymsymsymsymsymsymsymsymsymsymsymsymsymsymsymsymsymsymsymsymsymsymsymsy\n\nand                                                                             and\n\nThe above mentioned as ECDC's report contains a condensation of diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased diseased growth Guillain-Barre syndrome (but it is here to note what circulates and in Ellada to four-\n\nIn Ellada, with the 2022 release as the second-grade PCS, the second-grade PCS, the second-grade PCS, the second-grade PCS, the second-grade PCS, the second-grade PCS, the second-grade PCS, the second-grade PCS, the second-grade PCS, the second-grade PCS, the second-grade PCS, the second-grade PCS, the second-grade PCS, the second-grade PCS.",
      "start_page": 480,
      "end_page": 504
    },
    {
      "heading": "HiB/ Influenza Hemophilus vaccination",
      "text": "Haemophilus influenzae is an adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterous adulterated adulterous adulterous adulterous adulterous adulterated adulterated adulterated adulterated adulterated adulterated adultererated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adulterated adultererererererated adulterated adultererated adulterated adulterated adulterated adulterererererererated adulterated adulterated adulterated adultererererererererererererererererererererererated adulterated adulterererererated adulterererererererererererererererererererererererererererererererererererererated adulterated adulterererererererererererererererererated adultererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererererer",
      "start_page": 505,
      "end_page": 507
    },
    {
      "heading": "HPV/Human papillomavirus",
      "text": "There remains both the incidence and severity of HPV infection in this patient population.",
      "start_page": 507,
      "end_page": 507
    },
    {
      "heading": "HZV/ shingles vaccine",
      "text": "Emphasis                                                           .\n\nAccording to the latest report of the World Health Organization (WHO) in the report of the World Health Organization (WHO) in the report of the World Health Organization (WHO), in the report of the World Health Organization (WHO), the report of the World Health Organization (WHO) in the report of the World Health Organization (WHO), the report of the World Health Organization (WHO) in the report of the World Health Organization (WHO).",
      "start_page": 509,
      "end_page": 512
    },
    {
      "heading": "The respiratory syncytial virus the virus of the brochioli tida (respiratory syncytial virus, RSV) is",
      "text": "[                                                       [\n\n4 directional instructions of the American Society of Clinical Oncology (ASCO)\n\nZostavax Zostavax me no greater than 4 y You stop for a), Not d in future to 00, ACAM 2000 In case of a case e report antenides as to the virus Mpox, in s Imvanex",
      "start_page": 513,
      "end_page": 519
    },
    {
      "heading": "table under heading Covid19, a new special chapter dealing with Vaccines in oncology patients has been added,> (from previous page)",
      "text": "Row 1: Definition of Molecular Subtype Molecule (corresponding)Racian subtypes Clinically-pathologically-liked expression Row 2: Luminal A-liked expressionEstrogen receptor expression (ER), no hyperexpression HER2 High-expression progesteronic receptor (PR) Low Ki-67 or Molecular signature resulting in low-risk compatible Row 3: Luminal B-liked expression",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "table under heading 1. AC or EC>",
      "text": "Row 1: HER2-positive (non luminal)Yperexpression HER2 Without expression ER and PR Row 2: ‘Basal-like’NO expression ER and PR and without overexpression HER2.",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table under heading 1. AC or EC>",
      "text": "Row 1: Systemic therapy π Hypotype of rheumatic breast cancer Recommended treatment Row 2: Luminal A-likeHormonotherapy for most cases Row 3: Luminal B-likeChemotherapy in case of T3-4 tumors and/or 4 infiltrated lymph nodes. Chemotherapy followed by hormone therapy for most Row 4: Luminal B-like",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table under heading 1. AC or EC> (column 1)",
      "text": "Row 1: HER2-positive (non luminal) Row 2: ‘Basal-like’",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table under heading 1. AC or EC> (column 1)",
      "text": "Row 1: Systemic treatment π Subtype Row 2: Luminal A-like Row 3: Luminal B-like Row 4: Luminal B-like HER2-positive Row 5: HER2-positive (non luminal) Row 6: ‘Basal-like’",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table under heading cancer. J Clin Oncol 2001; 19:3103.> (from previous page)",
      "text": "Row 1: Breast Cancer. N Engl J Med. 2016; 375(18): 1738-1748 Row 2: Row 3: Sikov, WM, Berry, DA, Perou, CM, et al. Impact of the addition of carboplatin and/or bevacizumab to Row 4: neoadjuvant once-per-week paclitaxel",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table under heading Etotoside/Cisplatin>",
      "text": "Row 1: Vinorelbine/Cisplatin Vinorelbine25mg/m2D1, 8, q21d D1, Row 2: Cisplatin Gemcitabine/Cisplatin Gemcitabine80 mg/ m2 1250 mg/ m2q21d D1, 8, q21d D1, Row 3: Cisplatin Docex/Cisplatin Gemcitabine80 mg/ m2 1250 mg/ m2 1250 mg/m2q21d D2q21d D22q21d D1222D1D132333333334433333333333333334333333333333333333333433333333333333333333333333333333334333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333333",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "table under heading Etotoside/Cisplatin>",
      "text": "Row 1: Etoposide/Cisplatin Etoposide100 mg/ m2D1-3, q21d D1,",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "table under heading Etotoside/Cisplatin> (column 2)",
      "text": "Row 1: 25mg/m2D1, 8, q21d D1, Row 2: 80 mg/m2 1250 mg/m2q21d D1, 8, q21d D1, Row 3: 75/mg/m2 75 mg/m2q21d D1, q21d D1, Row 4: 75 mg/m2 500 mg/m2q21d D1,",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "table under heading Etotoside/Cisplatin> (column 2)",
      "text": "Row 1: 100 mg/ m2D1-3, q21d D1,",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "table under heading Etotoside/Cisplatin> (from previous page)",
      "text": "Row 1: Docetaxel/Carboplatin Docetaxel75 mg/ m2D1, q21d Row 2: Carbopatin Paclitaxel/Carboplatin PaclitaxelAUC 6 200mg/m2D1, q21d D1, q21d Row 3: Carboplatin Pemetrexed/Carboplatin Pemetrexed",
      "start_page": 88,
      "end_page": 88
    },
    {
      "heading": "table under heading Patients with General Status Index (PS) 2>",
      "text": "Row 1: Docetaxel/Gemcitamine Docetaxel100 mg/ m2D8, q21d Row 2: Gemcitabine Paclitaxel/Gemcitabine Paclitaxel1100 mg/ m2 200mg/m2D1,8, q21d D1, q21d Row 3: Gemcitabine Paclitabine",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "table under heading AVAiL>",
      "text": "Row 1: ECOG 4599 Row 2: Paclitaxel Carboplatin Bevacizumab200mg/m2 AUC 6 15mgkgDay 1;q21d Day 1;q21d Row 3: AVAiL Row 4: Cisplatin Gemcibine Bevacizumab80mg/m2 1250",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "table under heading CHEMETHERAPY MAINTENANCE> (from previous page)",
      "text": "Row 1: Pemetrexed500 mg/m2, d1, q21dIn patients who did not show progression of the disease after 4 cycles of first-line CHTH with platinum Row 2: Erlotinib150 mg/daycombination. In patients with activatory EGFR mutations and stable disease after 4 cycles of CHTH with platinum",
      "start_page": 94,
      "end_page": 94
    },
    {
      "heading": "table under heading CHEMETHERAPY MAINTENANCE> (from previous page)",
      "text": "Row 1: Erlotinib150 mg/dayFrom oral, continuously until disease progression or non-Row occurrence: Gefitinib250 mg/dayacceptable toxicity Oral, continuously until disease progression or non-Row 3: Afatinib40 mg/dayacceptable toxicity Oral, continuously until disease progression or non-Row 4:com",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "table under heading CHEMETHERAPY MAINTENANCE> (from previous page, column 2)",
      "text": "Row 1: Erlotinib Row 2: Gefitinib Row 3: Afatinib Row 4: Dacomitinib Row 5: Osimerinib Row 6: Erlotinib Ramucirumab Row 7: Erlotinib bevacizumab",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "table under heading C64>",
      "text": "Row 1:  Row 2: Table 1. Criteria for Memorial Sloan - Kettering Cancer Centre Row 3: Lost of one criteria, correlated with good prognosis Row 4: Presence of one or two criteria, correlated with intermediate prognosis Row 5: Presence of three or more criteria, correlated with poor prognosis Row 6: (Presence of more criteria)",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "table under heading C64> (from previous page)",
      "text": "Row 1:  Row 2: Table 2 International Metastatic RCC Database Consortium (Heng Criteria) Row 3: Lost of these criteria, correlated with good prognosis Row 4: Presence of one or two criteria, correlated with intermediate prognosis Row 5: Presence of three or more criteria, correlated with poor prognosis Row 6:",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "11: Harbors an EML4-ALK Composition and Responses to Crizocetinid. Case Rep Oncol 2014; 37:628 Row 2: 33. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: Row 3: Aphasoulis E, Kalofonos D, et al.\n\nIrinotecan plus carboplatin for patients with carcinoma of",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 1)",
      "text": "Row 1: Harb Row 2: 33. Bria Row 3: A ph Row 4: 34. Grec Row 5: treat Row 6: 35. Grec Row 7: plus Row 8: 36. Gros Row 9: unnn Row 10: 37. Poue Row 11: carc Row 12: 38. Cass Row 13: com Row 14: plus Row 8: 36.",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 2)",
      "text": "Row 1: bors an EML4-ALK; III Colonel Colonel, and Responses to Crizocetinib. Case Rep Oncol 2014; 11:628 Row 2: asoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: Row 3: hase II Hellenic Cooperative Oclinoma: 7:628 Row 2:",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "Row 1: Row 2: 42. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a",
      "start_page": 400,
      "end_page": 400
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "\n\nJ Clin Oncol 2000; 18:311. Row 20: 53. Sadowski highowv V, Millo C, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Row 21: Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neurodecritic Tum",
      "start_page": 400,
      "end_page": 400
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "9 Row 2: 58. Hicks RJ. Uses of molecular identified agents for the diagnosis, stigma and therapy of neuroendocrine Row 3: malaria. Cancer Imaging 2010; 10 Spec no A:S83 Row 4: 59. Strosberg JR, Coppola DS, Klimstra DS, Klimstra",
      "start_page": 401,
      "end_page": 401
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "Row 1: Parameter consideredMechanics used Row 2: FunctionalityActionals of Daily Living (ADL): Instrumental Activities of Daily Living (IADL) Row 3: Accompanying Diseases‘Timed Up and Go’ test Charlson Score Index (CSI) Row 4: Mental StatusCumulative Illness Rating ScaleGtricG",
      "start_page": 403,
      "end_page": 403
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "Row 1: CategoryParameters of PGAHealing Approach Row 2: Group 1: \"Capacity\" (\"fit\")No ADL and IADL dependence Without serious comorbiditiesOriginal treatment similar to younger Row patients 3: Group 2: \"Vulnerable\" (\"Vulnerable\")Absence of IADL geriatric syndrome but not ADL dependence",
      "start_page": 404,
      "end_page": 404
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "Row 1: Table 1. Examples of chemotherapeutic regimens at risk E.O., 20% Row 2:  Row 4: Cancer bladder Cyst(dd)MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) Row 5: Breast cancer",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 1)",
      "text": "20 Row 1: Table 1. P Row 2:  Row 3: Cancer ur Row 4: Cancer mas Row 5:  Row 6:  Row 7:  Row 8:  Row 9: Cancer bone  Row 10:  Row 11:  Row 12:  Row 13:  Row 14:  Cancer parch",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 2)",
      "text": "Forty-four: Row: Fourteen Row: Row 3: Row 4: Row 5: rook Row 6: Row 7: at Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: of Row 16: Row 17: Row 18: Row 19: Row 21: Row 22: Row 23: Row 23: Row 23: Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 3)",
      "text": "42: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 34: Row 26: Row 21: Row 21: Row 22: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23 Row 23 Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 4)",
      "text": "40 Row 1: peep χ Row 2: Row 3: Row 4: Row 5: husk Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 19: Row 21: Row 22: Row 23: Row 24: Row 24: Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 5)",
      "text": "40 Row 1: heaps Row 2: Row 3: Row 4: Row 5: s Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 19: Row 21: Row 22: Row 23: Row 24: Row 24: Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 6)",
      "text": "42: 40: 40: 50 Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row, Row, Row, Row, Row: Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 7)",
      "text": "48 Row 1: raps Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 21: Row 22: Row 23: Row 24: Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMETHERAPIC CHEES CAPE> (from previous page, column 8)",
      "text": "Row 1: of schematics at risk E.O. >20% Row 2:  Row 3:  Row 4: (dd)MVAC (methotrexate, vinplastine, d cisplatin) Row 5: TAC (docetaxel, doxorubicin, cyclophosp Row 6:  Row 7:  Row 7:",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 9)",
      "text": "37 Row 1: % Row 2: Row 3: Row 4: doxoru Row 5: phami Row 6: Row 7: hospha Row 8: Row 9: Row 10: ab) Row 11: Row 12: ycin, Row 13: Row 14: nomyc Row 15: famide Row 17: Row 17: Row 18: my, Row 19: Row 19: Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 10)",
      "text": "Row 27: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 26: Row 19: Row 19: Row 19: Row 19: Row 19: Row 19: Row 21: Row 22: Row 21: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 23: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 22: Row 23: Row 22: Row 23: Row 22: Row 22: Row 12",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 11)",
      "text": "Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 22: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 13: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 23: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row: Row 13: Row 13: Row: Row: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row: Row: Row 13: Row 13: Row 13: Row 13: Row 13: Row 13: Row: Row 13: Row: Row: Row: Row: Row: Row 13: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row: Row",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 12)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: Row 19: Row 20: Row 21: Row 22: Row 23: Row 24: Row 25:",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page)",
      "text": "Row 1:  Row 2:  Row 3: DT-PACE (dexamethasone, thalidomide, Row 4: Multiple myelomaciaplstin, doxorubicin, cyclophosphamide, etoposide )  bortezomib (VTD-PACE) Row 5: Non-small cell lung cancer",
      "start_page": 410,
      "end_page": 410
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 1)",
      "text": "Row 1:  Row 2:  Row 3: DT-PACE (dexamethasone, thalamido Row 4: Multiple myelomaciaplstin, doxorubicin, cyclophosph borezomib (VTD-PACE) Row 5: Non-small cell lung cancerDP (docetaxel, carplatin)",
      "start_page": 410,
      "end_page": 410
    },
    {
      "heading": "table under heading E. CHEMICAL THERAPY SCHEMES CAPE> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: omide, Row 4: hamide, etoposide )  Row 5: Row 6: Row 7: Row 8: Row 9: mide, etoposide) Row 10: Row 11: icin, etoposide) Row 12: Row 13: atin) Row 14: in)",
      "start_page": 410,
      "end_page": 410
    },
    {
      "heading": "table under heading E. CHEMIOTHERAPIC SCHEMES CAPE> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11:",
      "start_page": 410,
      "end_page": 410
    },
    {
      "heading": "table under heading 3 or higher High 7.1% 6.7%>",
      "text": "Row 1: Patient characteristicLisk Row 2:  Row 3: Site of cancer Row 4: Very high risk (stomach, pancreas)2 Row 5: High risk (lung, lymphoma, gynaecological, bladder, testicular, preliminary)1 Row 6: Pre-chemotherapeutic pellet",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading 3 or higher High 7.1% 6.7%>",
      "text": "Row 1: Total ScoreRisk CategoryDerivation cohort VTEValidation cohort VTE Row 2:  Row 3: 0Low0.8%0.3% Row 4: 1,2Intermediate1.8%2%",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading 3 or higher High 7.1% 6.7%> (column 1)",
      "text": "Row 1: Patient characteristic Row 2: Row 3: Site of cancer Row 4: Very high risk (stomach, pancreas) Row 5: High risk (lung, lymphoma, gynaecological, bladder, testicular, renal) Row 6: Pre-chemotherapeutic platet count 350,000 / lymphoma / gynaecological",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading 3 or higher High 7.1% 6.7%> (column 1)",
      "text": "Row 1: Total ScoreRisk CategoryDerivation cohort VTE Row 2:  Row 3: 0Low0.8% Row 4: 1,2Intermediate1.8%",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "table under heading 3 or higher High 7.1% 6.7%> (from previous page)",
      "text": "Row 1: Emetogenic activityEndorubicin Rhabidocrimodin Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhabidocritine Rhaboxicin Rhaboxicin Rhabvir Rhabvir Rhabvir Rhab",
      "start_page": 428,
      "end_page": 428
    },
    {
      "heading": "table under heading 3 or higher High 7.1% 6.7%> (from previous page)",
      "text": "Row 1: Breduximab bedotinRustuzumab emtansineTisotumab ventotin Row 2: PanitumabPertuzumab",
      "start_page": 429,
      "end_page": 429
    },
    {
      "heading": "table under heading 3 or higher High 7.1% 6.7%> (from previous page, column 1)",
      "text": "Row 1: Breduximab vedotinRustuzumab emtansine Row 2: PanitumumabPertuzumab",
      "start_page": 429,
      "end_page": 429
    },
    {
      "heading": "table under heading (80 mg PO daily at>",
      "text": "W.R.: W.R.: W.W.: W.R.W.: W.W.: W.W.: W.R.W.: W.W.: W.W.: W.W.: W.W.: W.W.: W.W.: W.W.: W.W.: W.W.: W.W.W.: W.W.: W.W.: W.",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at>",
      "text": "Row 1: Increased risk Row 2: vomiting Row 3:(>90%) Row 4:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at>",
      "text": "Row 1: PO or Row 2: a. 20 mg IV Row 3: Row 4: b. 12 mg if Row 5: we use Row 6: unpretentious/ fosaprepitant/",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 1)",
      "text": "Row 1:  Row 2: Ki Row 3:  Row 4:  Row 5: Increase vomiting>90%Increased Row 6: indirect Row 7: (>90% Row 8:  Row 9:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 2)",
      "text": "Row 1: Row 2: Row 3: danger Row 4: Row 5: Row 6: Row 7: a Mr Row 8: s Row 9: %) Row 10: Row 11: Row 12:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 3)",
      "text": "Row 1: Row 2: Row 3: The Eme Row 4: Row 5: Row 6: Row 7: Risk Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 4)",
      "text": "Row 1: Row 2: Row 3: you Row 4: Row 5: Row 6: Row 7: nos Row 8: Row 9: Row 10: Row 11: Row 12:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 5)",
      "text": "40 Row 1:  Row 2: Pharma Row 3:  Row 4:  Row 5: NK1R instead Row 6:  Row 7:  Row 8: Indecent Row 9:  Row 10:  Row 11:  Row 12:  Row 13: Indecent",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 6)",
      "text": "45 Row 1: Row 2: Row 3: acoon Row 4: Row 5: Row 6: Row 7: Tag Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Itty Row 17: Row 18: Row 19: Row 21: Row 22: Row 23: Row 23: Row 23: Row",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 7)",
      "text": "40  Row:   Row:   Row:   Row:   Row:   Row:  Row:   Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row:  Row: Row:  Row:  Row: Row: Row: Row: Row: Row: Row, Row: Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row, Row.",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading (80 mg PO daily at> (column 8)",
      "text": "##############################################################################################################################################################################################################################################################################################################################################################################################################################################################################################################################",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "table under heading 5-HT3 competitor (one of the following):>",
      "text": "42 Row 1:  Row 2:  Row 3: Olanzapine5 to 10 mg 5 to 10 mg on days 2 to 4. Row 4:  Row 5: Moderate risk of vomiting (30 to 90%) without-carboplatin5-HT3 antagonist (one of the following):  Row 6:  Row 7:  Row 9:",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 competitor (one of the following):>",
      "text": "Row 1: Moderate risk of vomiting Row 2: (30 to 90%) Row 3: no-carboplatin",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 competitor (one of the following):>",
      "text": "Row 1: PO Row 2: Row 3: 12 mg or IV (8 mg per os if using",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 competitor (one of the following):>",
      "text": "Row 1: Row 2: 8 mg per os or IV on days 2",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 competitor (one of the following):>",
      "text": "Row 1: Moderate risk of vomiting Row 2: (30 to 90%) Row 3: with carboplatin",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 competitor (one of the following):>",
      "text": "Row 1: Small risk of vomiting Row 2: (10 to 30%)",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 antagonist (one of the following):> (column 1)",
      "text": "13:  Row 2:  Row 3:  Row 4: Medium risk (30 to 90%) no-carbohydrateMedium risk Row 5: (30 to 90%) Row 6: No-carbohydrate Row 7:  Row 8:  Row 9: Medium risk (30 to 90%) with-carbohydrateMetrios",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 antagonist (one of the following):> (column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Hypnotic nemesis Row 5: Row 6: oplatin Row 7: Row 8: Row 9: Row 10: Hypnotic nemesis Row 11: Row 12: atin Row 13: Row 14: Row 15: Row 16: Hypnotic nemesis Row 17: Row 18:",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading 5-HT3 antagonist (one of the following):> (column 3)",
      "text": "42 Row 1:  Row 2:  Row 2:  Row 3: Olanzapine: 5 to 10 mg W on days 2 to 4 Row 4:  Row 5: h5HT3 antagonist (one of the next):  Row 6:  Row 8:  Row 9:  Row 11:  Row 11:",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "table under heading Grade 3 Serious:>",
      "text": "Row 1: Grade 1 Mild: Rash covering 10% BSA with or without symptoms (e.g. itching, feeling Row 2: Grade 2burn, pain) Moderate: Rash covering 10-30% BSA with or without symptoms (e.g. itching, feeling hot, pain), limits daily activities Rash covering >30% BSA without or with mild symptoms",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "table under heading Grade 3 Serious:>",
      "text": "Row 1: Row 2: General measures to support and monitor skin care, which may Row 3: prevent or minimize the severity of the rash associated with administration",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: Row 2: Use of loose, soft clothing and soft, comfortable shoes. Placement of gel bottoms. Row 3: Avoid long walks or intense exercise as well as applying large pressures and",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: SPF at least 30 minutes to 1 hour before exposure to the sun. Row 2: Avoid local medicines applied to treat the acne Row 3: (e.g. benzene peroxide).",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: Dermal Derm toxicityaCtlicinic tacoax iHkaotriatkat chelation disease or haematopoithiasis reduction in pneaTreatment Row 2: Alopecia- Result of direct toxicity of CHT in rapidly multiplying hair follicle cells. The overall incidence of alopecia after chemotherapy administration is estimated at 65%",
      "start_page": 452,
      "end_page": 452
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: more cytotoxic drugs. swelling of the papillary sinuses (swelling of the papillary sinuses)  Inflammation of the papillary sinuses (inflammation of the papillary sinuses)  Inflammation of the papillary sinuses (inflammation of the papillary sinuses)  The loss of the hair becomes more evident after the onset of the treatment.\n\n- Radiotherapy may have preceded a few weeks to 15 years before the development of this inflammatory reaction Skin findings: - Erythema, maculoplapid rash, blisters, exfoliation, necrosis (rarely) - Moderate power topical corticoids on the face, strong or very strong local corticoids on the rest of the trunk - Antihistamines Recurrence of symptoms does not always lead to the same.",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: Row 2:",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page, column 4)",
      "text": "Row 1: more cytotoxic drugs. - Inflammation of the skin is usually caused 7-10 days after the onset of the treatment. Inflammation of the sinuses can occur. - Inflammation of the hair becomes more evident 1 to 2 months after the onset of the treatment. Repeated chemotherapy cycles lead to total alopecia. - Alopecia is reversible. - Escape of the drug from the vessels to the surrounding tissues. - Frequency of appearance 0.1 – 6%, most common in children.",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: - Vlennogenitis, esophagitis, pneumonitis, if these parietal palpitations - parietal palpitations - parietal palpitations - most common lesions of the parietal sinuses - Symptoms of palpitations - palpitations of the palms and soles are observed.",
      "start_page": 454,
      "end_page": 454
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: Skin agents, treat Toxicity/ Pharmaceutical agentsClinical Characteristics H.Treatment Row 2: AEGcmFroe iindhei beixtaonrths MEC verbs inhibitorsIt is usually localized on the head and upper thoraxThoracic vultures and pustules, without pecs, usually localized on the head and upper thorax",
      "start_page": 454,
      "end_page": 454
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1:  isotretinoin 10-20 mg in the case of row: exudate vitreous vitreous vitreous vitreous vitreous vitreous vitreous vitreous vitreous vitreous vitreous vitreous vitreous vitreous vitreous vitreous vitreous vit.\n\n-No metastasis has been described by these tumors.- Surgical removal of lesions - Diathermy – papilloma cryotherapy Row 7: YBRpAodFe Rheumatitis- Painful subcutaneous nodules below-NSAFF",
      "start_page": 455,
      "end_page": 455
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page, column 4)",
      "text": "Row 1: - Isotretinoin 10-20 mg in case Row 2: non-responsiveness to tetracyclins Dizziness parietal rashes - Moisturizing preparations without aromas - Local corticoids in case of eczema of lesions. Row 3: Grade 1 - Local application of antibiotics and antiseptics (chlorhexidine, potassium permanganate, iodide povidone, chlorin solution)",
      "start_page": 455,
      "end_page": 455
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: MKIs- Systemic corticoids (prednisone Row 2: LCDeuKk4th/ 6 inhibitors- White spots, asymptomatic - May be localized at0.5-1 mg/kg qd to resolution of rash - Monitoring - Local corticoids - Cream pimecrolims-tacrolims",
      "start_page": 456,
      "end_page": 456
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1: Dermal Toxicity/ Pharmaceutical FactorsCliniferous complexesFluoridal complexesFluoridal complexesFluoridal complexesFluoridal complexesFluoridal complexesFluoridal complexesFluoridal complexesFluoridal complexesFluoridal complexesFluoridal complexesFluoridal complexesFluoridal complexesFluoridative complexesFluoridoridativesFluoricsFluoricsFluoricsFluoricsFluoricsFluoricsFluoricsFluoricsFluoricsFluoricsFluoricsFluoricsFluoricsFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFuriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFrFluoriculenceFluorinFluorinFluorinFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoriculenceFluoricsFluorin\n\n- Systemic corticoids in unresponsive (0.5-1 mg/kg/day prednisolone) Row 8: bullogen of the mouth",
      "start_page": 457,
      "end_page": 457
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page, column 4)",
      "text": "Row 1: Clinical Characteristics Row 2: Row 3: See C1 Row 4: See C2 - Erythematous parietal plaques with mild exfoliation - Spotting mainly on the extremities - Accompanied by intense Row 5: pruritus - Well circumscribed, circular, red plaques with a silvery leap. -Distribution on the elbows, knees, hairy. - All types of psoriasis",
      "start_page": 457,
      "end_page": 457
    },
    {
      "heading": "table under heading Grade 3 Serious:> (from previous page)",
      "text": "Row 1:",
      "start_page": 458,
      "end_page": 458
    },
    {
      "heading": "table under heading NTRK> (from previous page)",
      "text": "Row 1: teBlaikthomyus sedophore Specific dose administration may be impaired or may be impaired in the treatment of attenuated urination, attenuated urination, attenuated urination, attenuated urination, attenuated urination, attenuated urination, attenuated urination, attenuated urination. Row 2: Mild-moderate: GER 30-89ml/min - Dependent",
      "start_page": 472,
      "end_page": 472
    },
    {
      "heading": "table under heading NTRK> (from previous page)",
      "text": "Row 1: OpiateActive, renally excreted metabolitesRemoves by hemodialysisSafe and effective in blood-diluted Row 2:  Row 3: MorphineYesAvoid as much as Row 4: Become Row 5: Hydromorphone(Yes)YesYes, with caution Row 6: OxycodoneYes(Yes)know",
      "start_page": 472,
      "end_page": 472
    },
    {
      "heading": "table under heading NTRK> (from previous page)",
      "text": "Row 1: Responsive relationshipRow recommendation level 2: p.omorphine on p.ooxycodone1.5:1Strong Row 3: p.omorphine on buprenorphineTTS75:1Patient Row 4: p.omorphine on fentanylTTS100:1Strong",
      "start_page": 474,
      "end_page": 474
    },
    {
      "heading": "table under heading NTRK> (from previous page)",
      "text": "Row 1: Row 2: Competitors5HT3 is the choice drug for the treatment of acute nausea and vomiting",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading NTRK> (from previous page)",
      "text": "Row 1: Row 2: Risk assessment for symptoms and selection of appropriate antiemetics Row 3: Recommendation for adequate and regular use of antiemetics Row 4: Practical measures: Avoiding exposure to odors, small frequent meals, good oral hygiene, calm Row 5: environment, avoid alcohol Row 6: Treating symptoms initially with an antiemetic drug based on the alleged cause Row 7:",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 1)",
      "text": "Row 1: Row 2: Competitors5HT3 is the choice drug for the treatment of acute nautilus",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 1)",
      "text": "Row 1: Row 2: Risk assessment for symptoms and selection of appropriate antiemetics Row 3: Recommendation for adequate and regular use of antiemetics Row 4: Practical measures: Avoiding exposure to smells, small frequent meals, good hygiene in Row 5: environment, avoid alcohol Row 6: Treating symptoms initially with an antiemetic drug on the basis of ecosmose Row 7: Using each other",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 2)",
      "text": "Row 1: Row 2: ja and vomiting",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: toma, calm Row 5: Row 6: one cause Row 7: Row 8: Row 9: Range Row 10: Row 11: the Row 12: Row 13:",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "table under heading NTRK> (from previous page)",
      "text": "Row 1: Antiemetic drugs Row 2: Row 3: Antagonists 5HT3: ondasetron , granisetron, palonosetron Row 4: Antagonists NK1: aprepitant , fosaprepitant Row 5: Corticosteroids: dexamethasone Row 6: Dopamine receptor antagonists: halomoid proproids,",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 1)",
      "text": "Row 1: Antiemetic drugs Row 2: Row 3: Competitors 5HT3: ondasetron , granisetron, palonosetron Row 4: Competitors NK1: aprepitant , fosaprepitant Row 5: Corticosteroids: dexamethasone Row 6: dopamine receptor antagonists: haloperid,",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: n Row 4: Row 5: Row 6: etiquette -metoclopr",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: ramide",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: e, dom",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 5)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6:mperid",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 6)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: done",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading NTRK> Gene fusion (from previous page, column 7)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6:",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "table under heading Face>",
      "text": "Row 1: Stimulants laxativesBisacodylWarning use if there is a possibility of Sennaenteric obstruction Row 2: Faecal softenersSodium docusate Row 3: Osmotic laxativesLiquid paraffin Macrogol",
      "start_page": 480,
      "end_page": 480
    },
    {
      "heading": "table under heading Face> (from previous page)",
      "text": "Row 1: Row 2: 2. Eric J. Roeland, Kari Bohlke, Vickie E. Baracos, Eduardo Bruera, Egidio del Fabbro, Suzanne Dixon, Marie Row 3: Fallon, JrnHerrstedt, Harold Lau, Mary Platek, Hope S. Rugo, Hester H. Schnipper, Thomas J. Smith.",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "table under heading Face> (from previous page)",
      "text": "Row 1:  Row 2: 14. Loprinzi CL, Kugler jacket JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK,n JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK:",
      "start_page": 486,
      "end_page": 486
    },
    {
      "heading": "table under heading Face> (from previous page)",
      "text": "Row 1:  Row 2: 1. Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, Schnipper HH, Lacchetti C, Ligiment JA, Row 3: Lyman GH, Ogaily MS, Pirl WF, Jacobsen PB, American Society of Clinical Oncology.Lysen GH, Ogaily MS, Pirl WF, Jacobsen PB, American Society of Clinical Oncology.",
      "start_page": 488,
      "end_page": 488
    },
    {
      "heading": "table under heading Face> (from previous page)",
      "text": "Row 1: J Clin Oncol. 2014;32(17):1840. Epub 2014 Apr 14 Row 3: 2. Cella D, Davis K, Breitbart W, Curt G, Fatigue Coalition. Cancer-related Fatigue: prevalence of proposed Row 4: diagnostic criticism in United States sabotage",
      "start_page": 488,
      "end_page": 488
    },
    {
      "heading": "table under heading Face> (from previous page)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10:",
      "start_page": 488,
      "end_page": 488
    },
    {
      "heading": "table under heading Face> (from previous page)",
      "text": "Row 1: Scotland, Healthcare Improvement Scotland 8. Row 2: 3. Lipowski ZJ Delirium (acute Consular states).JAMA. 1987;258(13):1789. Row 3: 4. Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. AMC.",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "table under heading The respiratory syncytial virus the virus of the brochioli tida (respiratory syncytial virus, RSV) is > (from previous page)",
      "text": "Row 1: DiseasesCommercial name of the vaccineSynapismChrosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis oscillosis osma oscillosis oscillosis oscillosis oscillosis oscillosis os",
      "start_page": 517,
      "end_page": 517
    },
    {
      "heading": "table under heading The respiratory syncytial virus the virus of the brochioli tidas (respiratory syncytial virus, RSV) is > (from previous page, column 4)",
      "text": "Row 1: RecommendationChronicsObservations Row 2: Adequate vaccinations for the first time, adequate vaccinations for the first time, adequate vaccinations for the first time, adequate vaccinations for the first time, adequate vaccinations for the first time, and adequate treatment for the second week.",
      "start_page": 517,
      "end_page": 517
    },
    {
      "heading": "table under heading The respiratory syncytial virus the virus of the brochioli tida (respiratory syncytial virus, RSV) is > (from previous page)",
      "text": "Row 1: Hepatia tida B /HBVEngerixIn the womb of the sick, let it be in the womb of the sick, let it be in the womb of the sick, let it be in the womb of the sick, let it be in the womb of the sick, let it be in the womb of the sick, let it be in the womb of the sick, let it be in the womb, let it be in the womb, let it be in the environment, in the womb, in the womb, in the womb, and in the womb, in the womb, in the blood, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the blood, in the womb, in the womb, and in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, and in the womb, in the womb, and in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the disease, in the womb, in the disease, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the disease, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, in the womb, the womb, in the womb, in the disease, in the womb, in the disease, in the womb, in the womb, in the disease, in the womb, in the womb, in the disease, in the disease, in the disease, in the disease, in the disease, in the disease, in the disease, in the disease, in the womb, in the disease, in the disease, in the disease, in the disease, in the womb, in the disease, in the womb, in the disease, in the womb, in the disease, in the disease, in the disease, in the disease, in the disease, in the",
      "start_page": 518,
      "end_page": 518
    },
    {
      "heading": "table under heading The respiratory syncytial virus the virus of the brochioli tidas (respiratory syncytial virus, RSV) is > (from previous page, column 6)",
      "text": "Row 1: In sickness with others rather than sons of danger mind (sexual , professional , environmental suffix, use drug , time for liver disease aunt, Row 2: sugar dia) In sickness with others than sons of danger mind (sexual , professional , environmental suffix , use",
      "start_page": 518,
      "end_page": 518
    },
    {
      "heading": "table under heading The respiratory syncytial virus the virus of the brochioli tida (respiratory syncytial virus, RSV) is > (from previous page)",
      "text": "Row 1: Anemylium Varivax                                             Row 2:                                    .",
      "start_page": 519,
      "end_page": 519
    },
    {
      "heading": "table under heading The respiratory syncytial virus the virus of the brochioli tidas (respiratory syncytial virus, RSV) is > (from previous page, column 5)",
      "text": "Row 1: nos) and have no disease tendinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis Row 2: niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinosis niacinitis niacinosis niacinitis niacinitis nia nia nia nia nia niacinitis nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia nia",
      "start_page": 519,
      "end_page": 519
    }
  ]
}